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ABSTRACT 
    Background: Subarachnoid haemorrhage is a devastating disease with high morbidity and mortality 
despite novel treatment options are available. There are no established methods to measure the brain 
damage occurring due to the bleed and its complications and to predict early neurological outcome of the 
disease. Genetic predisposition is suggested as one of the determinants of outcome.  
    Aim: The aim of this thesis was to investigate nine biochemical neuromarkers’ course and 
development in the early phase of aneurysmal subarachnoid haemorrhage (aSAH) with special 
emphasis on C-reactive protein (CRP) and to test if they could be used as markers of disease 
progression and possibly long-term outcome. As a tool, we aimed to test a novel multiple biochip array 
for simultaneous monitoring these markers. Finally, we intended to elucidate the effect of two 
chromosomes with different genetical polymorphisms on the incidence and development of the disease. 
(Apolipoprotein E and region 9p21) 
    Patients and methods: We have consecutively included patients admitted to the Sahlgrenska 
University Hospital for SAH, where the causative reason was a ruptured intracranial aneurysm. We have 
recorded the patients’ admission status with neurological scales and radiological scores for the severity 
of the haemorrhage. We collected blood sample for determining genetics and continued to collect serum-
samples for biochemical marker detection on day0-4, 6, 8, and finally once on days 11-14. We noted the 
complication cerebral vasospasm (CVS). A long-term follow-up was performed after one year with 
detailed neurological examinations. For the genetic studies matching controls were recruited among 
healthy individuals.  
    Results: In 98 endovascularly treated patients, we described the pattern of CRP increase after aSAH. 
It peaked on day3 with a mean value of 53 mg/l and decreased successively without normalising. This 
pattern was not dependent of infectious status. We noted a difference in increase between the patients 
with favourable and unfavourable disease development (i.e. CVS) and long-term outcome, focal 
neurology and need of assistance with daily activities (ADL) after one year. In a multivariate regression 
model with initial neurology, radiological severity, CRP was the only parameter showing significant OR. 
(OR: 1.25/10 units). We could present a predictive curve for poor outcome in relation to CRP values. 
Furthermore, we tested a 9 potential neuromarker-containing panel in a test series of 41 patients. Six of 
these markers, TNFR1, IL-6, hs-CRP, DDMR, NGAL and FABP showed significant correlation to CVS 
development and different outcome results. Four of the markers (TNFR1, hs-CRP, NGAL & FABP) had 
moderate or good predictive qualities. In a genetic study, ApoE polymorphism on the 19th chromosome, 
did not present any effect either on the incidence of aneurysm rupture or CVS development and outcome 
parameters after aSAH in 154 patients and 221 controls. However we have found a single nucleotide 
polymorphism (SNP) rs10757278 on the 9th chromosome p21 region, which even after controlling for 
hypertension and smoking showed a significant negative effect on aneurysm rupture in 183 patient and 
366 controls. 
    Conclusion: CRP proved to be a useful marker for following the course of aSAH and may be 
applicable for predicting complication or outcome. The tested biochip-neuropanel could be a valuable 
addition to neuro-monitoring during the initial phase of the aSAH. Finally, not APOE polymorphism, but a 
genetic variant on 9p21 chromosome region affected negatively the risk of aneurysm rupture in West 
Sweden. 
Keywords: subarachnoid haemorrhage, biochemical markers, genetical markers, 
outcome 
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POPULÄRVETENSKAPLIG SAMMANFATTNING  
Biokemiska och genetiska markörer efter 
subarachnoidalblödning  
 
Subarachnoidalblödning är en typ av hjärnblödning, som förekommer mellan 
hjärnan och spindelnäthinnan, utgående ifrån ett brustet pulsåder-bråck på 
skallbotten och är ett förödande sjukdomstillstånd. Cirka en tredjedel av 
patienter, som drabbas dör, en tredjedel ådrar dig svåra neurologiska men och 
en tredjedel återhämtar sig så, att de kan ta hand om sig själva. Det existerar 
inga metoder att mäta den hjärnskada som blödningen och dess svåra 
komplikationer åstadkommer samt vi kan inte prediktera sjukdomsförloppet i 
ett tidigt skede. Man har dock visat, att genetiska faktorer påverkar hur 
hjärnan återhämtar sig efter sjukdomen. 
Ett kroppseget äggvite-ämne, C-reaktiv protein, som hittills använts för att 
följa infektion i kroppen, kunde vi påvisa att koncentrationerna i blodet av 
denna följer kroppens hjärnblödningsförlopp tidigt under sjukdomen. Hos 
hundra blödningsdrabbade patienter mätte vi variationer i nivån av detta 
protein och observerade olika förlopp mellan de komplikationsdrabbade 
patienterna med dålig prognos samt de som återhämtade sig bra efter 
sjukdomen. Utifrån denna skillnad, kunde vi beräkna en prognostisk modell, 
som så tidigt som två dagar efter blödningen, kunde förutse hur stor risk 
patienten hade för en dålig sjukdomsprognos ett år efter insjuknandet. Denna 
prognostiska egenskap var oberoende om patienten blev infekterad eller inte 
under vårdförloppet.  
Vi har dessutom testat en ny biochip styrd mätmetod för 9 olika små 
proteiner, som man samtidigt kunde analysera från en droppe blod i denna 
hjärnblödningsdrabbade patientgrupp. Vi ville testa om dessa markörer kunde 
komplettera eller ersätta de andra mycket farligare mätmetoderna (kateter-
tryckmätning i hjärnan, upprepade röntgenkontroller) som används för att 
förutspå komplikationer och sjukdomsprognos efter genomgången sjukdom. 
Vi kunde konstatera att sex av dessa ämnen visade en nära korrelation till den 
långsiktiga sjukdomsprognosen efter sjukdomen och 4 av dessa kunde med 
IV 
en stor säkerhet förutspå denna. Dessa fynd bereder plats för ett införande av 
denna undersökningsmetod på sjukhuset.  
Härutöver har vi testat två genetiska variationer på två olika kromosomer och 
tittat på deras effekter på bristning av pulsåderbråck i hjärnans kärl och 
komplikation samt sjukdomsprognos efter spindelvävshinneblödning. Den 
ena variation (Apolipoprotein E), som är känd för sin negativa påverkan på 
sjukdomsförloppet vid traumatiska hjärnskador och hjärnpropp (stroke) samt 
vid Alzheimers sjukdom, visade dock ingen effekt på denna typ av blödning. 
Den andra genetiska variationen, på den 9:e kromosomens p21 region visade 
däremot en statistiskt säkerställd negativ effekt på kärlens bristningstendens. 
Dessa studier hjälper oss att bättre förstå de ärftliga faktorer, som påverkar 
hur våra hjärnor hanterar dessa blödningar. 
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INTRODUCTION 
I. Background 
Aneurysmal subarachnoid haemorrhage 
(aSAH) is a devastating neurological 
emergency leaving “one third of the affected 
patients dead, one third with severe handicap 
and merely one-third with a good recovery” 
according to the 1950’s well-known Swedish 
pioneers of neurosurgery Gösta Norlén and 
Herbert Olivecrona  (Norlen and Olivecrona, 
1953). This particular entity of haemorrhagic 
stroke has been studied in thousands of 
scientific studies and experiments from 
Walton’s prognostic description (Walton, 
1952) – 15% mortality in the first 24 h, 12% 
after 1 week, 14% after 2 weeks and 11% 
after 4 weeks, giving a cumulative 
percentage of 32% mortality in the first 
month – until Magni’s study, fairly recently 
describing a 6 month mortality of 34% 
(Magni et al., 2015). The overall outcome 
figures remain surprisingly unchanged 
throughout the years. From a sceptic’s point 
of view, no progress has been achieved 
during the work of two generations. From the 
optimist’s point of view however, we have 
come a long way and in the fields of 
diagnostics, treatment, care and rehabilitation 
the subarachnoid haemorrhage patients 
receive an entirely different attention 
compared to 60 years ago. The truth lies 
nevertheless somewhere in between. 
Although computed tomographic- (CTA), 
magnetic resonance imaging- (MRA) and 
digital subtractions-angiography (DSA) are 
available for diagnostics, micro-neurosurgery 
with titanium aneurysm-clips and 
interventional neuroradiology with titanium 
coils, and titanium-alloy stents are used in 
therapy approaches, patients are cared for 
and monitored in specialised neuro-intensive 
care units and after acute ward, recovery is 
undertaken in neuro-rehabilitation centres, 
the outcome after aSAH is still bleak. One 
could argue, that with better and more 
efficient ambulance service more patients 
survive the initial ictus and reach hospital in 
a worse condition (worse initial neurology), 
the patients are older and more affected by 
co-morbidity, and reach therapy centres with 
intra-ventricular haematomas, which was 
impossible earlier (Naval et al., 2013). If the 
outcome-study is controlled for all these 
parameters, then the outcome after aSAH, 
has indeed improved (Macdonald, 2013; 
Grunwald et al., 2014; Naval et al., 2013). 
The incidence of aSAH in the world is 
around 9 of 100,000 individuals, but it has a 
considerable geographical (Steiner et al., 
2013) and socio-economical (Jakovljevic et 
al., 2001) variation. In Finland and Japan, 
incidence over 20/100,000 were reported. 
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productivity loss and informal care (Joo et 
al., 2014).  
A. Mechanism 
Subarachnoid haemorrhage is a result of a 
bleeding from a blood-vessel within the 
subarachnoid space (Fig 1). The source of the 
bleeding can be traumatic, from around the 
injured brain parenchyma (contusion-leak 
from parenchymal capillaries), venous e.g. 
from the subarachnoid venous network 
often described as, bridging-veins or 
perimesencephalic/prepontin bleed, 
localised to those basal cisterns with 
possible extension to the suprasellar 
cistern (Schievink et al., 1994) or  
arterial from small subarachnoid arteries 
(malign hypertension bleed) frequently 
with a parenchymal component. Most 
often, however (ca. 85%) the 
subarachnoid haemorrhage originates 
from the large arteries on the base of the 
scull, the circulus arteriosus Willisii and 
its branches. (Fig. 2) These 
haemorrhages have an entirely different 
disease development and associated 
with a far more severe outcome. Our 
studies are dedicated to further explore 
these types of bleeds.  
The largest ever International Study of 
Unruptured Intracranial Aneurysms – 
the ISUIA study (Wiebers et al., 2003) 
– investigated 4060 patients in 59 American, 
Canadian and European centres. The 
localisation and site of the aneurysms were 
found to be of importance for risk of rupture. 
The most common sites were the internal 
carotid artery (CA) 38.3%, middle cerebral 
artery (MCA) 29.1%, ant. communicating 
artery (A.Com.A.) and ant. cerebral artery 
(ACA) 12.3%, post. communicating artery 
(P.Com.A) 8.5%, basillar tip artery (BA) 
7.0%, vertebrobasillar arteries [vert. artery 
(VA), post. inf. cerebellar artery (PICA), 
post. sup. cerebellar artery (PSCA)] 4.9%. 
Figure 2. Circulus arteriosus Willisii on the base of the skull, 
the four main supplying arteries to the brain and the most 
common localisations of intracranial aneurysms. Modified after 
Rhoton, 2002. 
A.Co.A.: Ant. Communicating Artery  
A.C.A.: Ant. Cerebral Artery (1+2=>12%) 
M.C.A.: Middle Cerebral Artery (29%) 
C.A.: Int. Carotid Artery (38%) 
P.Co.A: Post. Communicating Artery (8.5%) 
P.C.A.: Post. Cerebral Artery 
B.A.: BasillarArtery (+ SCA) (7%) 
V.A.: Vertebral Artery (+PICA +AICA)(5%) 
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This corresponds to a life-time risk of a 
haemorrhage of 0.5-1 per cent. Many risk 
factors have been identified in this 
population cohort (Vlak et al., 2013), and the 
four strongest are independent in a 
multivariable model: current and recent 
smoking (OR: 6.0), hereditary history of 
SAH (OR: 4.0), hypertension (OR: 2.4), 
hypercholesterolaemia (OR: 2.0). If age and 
gender are added to these risk factors, life-
time risk can increase up to 7.2 %. A large 
epidemiological study on the Global Burden 
of Diseases (GBD 2010) (Krishnamurthi et 
al., 2014) showed 5.3 million new cases of 
haemorrhagic stroke (HS) occurring yearly 
with an overall mortality of 3 million deaths 
world-wide. They could show a global 
increase of new HS patients with 47% and an 
increase of age-standardised incidence of 
18.5% but the majority of 
increase is noted in the 
low/middle-income counties 
(LMIC) 86%, where also 
the 63% of the deaths 
occurred. In fact, the high-
income countries (Europe, 
N-America and Australasia) 
could demonstrate an 8% 
decrease of HS incidence 
and mortality by 38% in the 
last two decades. There is 
some light shining through 
the darkness though, as even 
LMIC demonstrated a reduction in mortality 
of HS-s by 23%. It is interesting to note that 
there are 62.8 million disability-adjusted life 
years lost in the world yearly because of HS 
and about one fifth is due to SAH. The 
majority of this life-burden however is 
placed on the LMIC (86%).  
It does not mean, however that HIC spend 
less money on treatment and rehabilitation of 
SAH patients. On the contrary, according to 
the Nationwide Inpatient Sample database, 
the welfare-system in the USA spends an 
astounding 2 billion dollars only on acute 
hospital management of SAH patients. (Hoh 
et al., 2010) It is nonetheless only a fraction 
of the total costs associated with these 
patients as studies of indirect expenditure 
show an additional 30-97% extra expense for 
Figure 1. Subarachnoid space with the cerebral cortex. (Adapted from 
the Univ. of Utah, USA) 
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This corresponds to a life-time risk of a 
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Figure 1. Subarachnoid space with the cerebral cortex. (Adapted from 
the Univ. of Utah, USA) 
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1. Xanthochromia  
Lumbar puncture is still performed in the 
majority of patients presenting with a 
thunderclap headache and negative CT 
scan to identify or rule out subarachnoid 
haemorrhage. The reason is that only 8-
12% of patients with sudden headache and 
no neurological deficit suffer from an 
aSAH, and 40-50% of aSAH patients are 
presented with only headache and no 
other neurological symptoms.(Edlow and 
Fisher, 2012). For reliable result, the 
cerebrospinal fluid (CSF) has to be 
centrifuged immediately to prevent in 
vitro lysis of red cells with release of 
oxyhemoglobin. Thereafter 
spectrophotometry is used to differentiate 
the bilirubin absorption on 456 nm 
wavelength from oxyhemoglobin’s 415 nm 
(Fig 3). The former is 
pathognomonic for subarachnoid 
haemorrhage; the latter may be a 
remnant of a traumatic 
puncture.(Nagy et al., 2013) 
2. CT scan 
CT scan is the golden standard for 
SAH diagnostics. (Fig. 4) The 
technology of computed scanning 
is a fast forward motion in 
development, where the different 
companies are already 2-3 
generations ahead of the current 
clinical practice. We use currently 
from 4th to 7th generation CT 
scanners with fan to cone shape beam and 
detector array in access of 500 (the latest up 
Figure 3. CT scan of a suspected aSAH, with hydrocephalus 
development. The “crab of death” a typical sign of 
subarachnoid haemorrhage. 
Figure 4 Xanthochromia after subarachnoid haemorrhage. Note the 
bilirubin absorptions peak, presented as a shoulder at 475 nm. 
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Altogether the anterior circulation was four 
times more affected with nearly 80% of 
aneurysm formations; the potentially more 
dangerous posterior circulation was involved 
in 20.4% of cases. Annual rupture rate 
increased with the size of the aneurysm in the 
anterior circulation from 0.5% with size 7-12 
mm to over 8% if the size were larger than 
24 mm. In the posterior circulation it was 
even larger risk for rupture, it extended from 
2.9% (7-12mm) to over 10% in the large 
ones.  
Although the demographical and 
morphological aspects of aneurysm rupture 
have been widely investigated, the causative 
mechanisms are more scarcely debated. One 
of the main reasons the intracranial vessels 
behave differently, is because their 
histological structure is unlike any other 
vessels in the body. The adventitia, the outer 
layer of the vessels comprises of connective 
tissue, vasa vasorum and autonomic nerves, 
although the cerebral vessels, entering the 
subarachnoid space change their adventitia to 
leptomeningeal cells. This way they are 
bereaved from their elastic limiting shell as 
they cross the dura mater. The mesothelium 
is similar in its structure to other arteries, 
with smooth muscles as main constituent; 
and the endothelium has pronounced anti-
atherogenic, anti-platelet aggregation, anti-
adhesion and vasoregulatory properties. 
(Chalouhi et al., 2012) 
Other factors like local trauma (Pereira et al., 
2013), infections (Krings et al., 2008), low 
grade inflammation (Tulamo et al., 2011) 
and first of all genetic factors (Caranci et al., 
2013) have been discussed as causative 
agents.  
 
B. Diagnosis 
The diagnostic investigations after a 
suspected subarachnoid haemorrhage does 
not belong among the main topic of this 
thesis, although as inclusion and exclusion 
criteria, most of these procedures were 
mentioned and referred to in the Papers. I 
decided therefore to give a short summary of 
the examinations used in the clinical praxis. 
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pictures is well in the parity of a medium 
quality DSA.  
5. Digital subtraction  
angiography (DSA) 
It is the most advanced and best mapping 
possibility of the imaging systems. DSA is 
rather invasive, as it requires a puncture of a 
major artery (often the Femoral artery) and a 
microcatheter which is advanced through the 
aorta and up to both Carotid arteries by a 
neuroradiologist. The pictures are obtained 
with a rotational, often bi-plane X-ray image-
taking while a coordinated injection of 
radiological contrast is performed (Fig.6). 
One can visualise each and every section of 
the intracranial vessel-system and perform a 
detailed 3D mapping. The 
patients have to co-
operate fully or to be 
given general anaesthesia 
in order to achieve the 
immobility required for 
the superb quality 
pictures. Unfortunately 
the investigation puts 
some strain on the 
endothelium of the 
vessels and burdens the 
microtubuli of the kidneys 
with a potentially 
nephrotoxic contrast 
agent. It is not uncommon 
to notice a contrast-
leakage from the aneurysm during the 
investigation, which is another term for re-
bleeding.  
 
C. Treatment 
The European Stroke Organisation has 
recently issued guidelines on the treatment 
and management of intracranial aneurysms 
and SAH. (Steiner et al., 2013) Our routines 
at Sahlgrenska University Hospital consider 
these guidelines as minimum requirements. 
The treatment efforts are aimed at three 
different directions; 1) to prevent re-bleeding 
2) to prevent complications 3) to treat 
complications.  
Figure 6. Bi-plan Digital Subtraction Angiography (DSA) equipment for mapping 
intracranial aneurysms. (Siemens) 
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to 2400) in rotational array or in static 
detectors all around. The 6th generation, so 
called helical CT with source/detector 
pairwise rotation and the 7th generation 
multi-slice CT scanners can give 17 slices 
per second and is fast enough to examine the 
heart between beats.  Studies started to 
emerge, which showed that sensitivity and 
specificity of 3rd generation and newer CT 
scans are sufficient to diagnose or exclude 
SAH not later than 6 hours after the onset of 
symptoms, entirely on the basis of the scan if 
neuroradiological expertise was at hand. 
(Backes et al., 2012).     
3. CT angiography (CTA) 
The latest 5th and 6th generation 
CT scanners with their speed of 
scanning and their software 
interface enabled to perform not 
only a synchronised contrast X-
ray scan, but a high quality 3D 
reconstruction of the intracranial 
vessel system, and a first 3D 
picture of a potential vessel 
malformation. Many times the 
quality is good enough to set the 
diagnosis and initiate the 
treatment. There are some voices 
however; speaking out that CT 
angiography should be used with 
caution to rule out aneurysm 
initially, because of the risk of diagnosing 
asymptomatic aneurysms instead of a 
haemorrhage. (Edlow and Fisher, 2012) 
4. MRI Angiography (MRA) 
Magnetic resonance imaging with magnetic 
contrast angiography is not an emergency 
examination of acute subarachnoid 
haemorrhage investigation. Nevertheless it is 
a useful method of mapping an unruptured 
aneurysm before therapy measures are taken, 
or if neuro-navigational equipment is planned 
to be used (Fig. 5). Another indication could 
be severe radiological contrast 
hypersensitivity, which makes it impossible 
to perform either CTA or digital subtraction 
angiography (DSA). The quality of the 
Figure 5. Magnetic Resonance Imaging Angiography of the Circulus Willisii. 
Three aneurysms are visible. 
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refined by Kenichiro Sugita at the Nagoya 
University in the middle of the 1970-s 
(Sugita et al., 1984), is applied to the neck of 
the aneurysm, thereby obstructing the flow to 
it (Fig. 7). 
2. Endovascular coiling 
Endovascular treatment of an aneurysm 
begins the same way as a DSA, i.e. a 
puncture in one of the femoral arteries and 
navigating up a catheter via the aorta into the 
carotid/vertebral arteries and in this case a 
microcatheter further to the proximity of the 
aneurysm. Through this microcatheter one 
can fill the cavity of the aneurysm with 
flexible detachable platinum coils designed 
by Guido Guglielmi in the 1980s. (Guglielmi 
et al., 1992) After his concept the coils are 
named Guglielmi Detachable Coil (DGC) 
and following the FDA’s approval in 1995, 
more than 140 different versions, coatings 
and application-platforms are manufactured. 
The procedure was a major step forward in 
micro-invasive vascular neurosurgery. 
Depending on the centres routines and 
competence endovascular coiling represents 
now between 50-80% of all aneurysm 
treatment modalities. A few years later, in the 
beginning of the 1990s, the same institute in 
the UCLA presented micro-stents in 
combination with coiling (Turjman et al., 
1994). It allowed treating even the wide-
necked aneurysms, which previously had 
solely been the neurosurgeon’s domain 
(Fig.8).  
3. Conservative 
treatment 
A few patients, approximately 2 - 
4 % of the admitted subarachnoid 
haemorrhage cases do not 
undergo active 
neurosurgical/interventional 
treatment because of an 
accumulation of encumbering 
circumstances e.g. extremely high 
age, poor neurological income 
status (H&H - 5, WFNS – 5, GCS 
< 5) and/or other severe 
comorbidity where general 
anaesthesia would deteriorate 
their condition. These patients receive basic 
Figure 8. Combined stent, coil and surgical clip in a complicated 
aneurysm case in the Mayfield Clinic, Cincinnati, Ohio 
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To prevent re-bleeding 
It starts immediately after first physician 
contact of the patient through stabilising 
his/her condition, ensuring adequate 
oxygenation, and circulation. If needed, 
airways have to be secured and artificial 
ventilation started.  Nearly one third of the 
patients have initial loss of consciousness 
and one fourth have convulsive seizures. 
(Fung et al., 2015) It is imperative to cease 
these seizures to continue the patient 
management. To establish monitoring is 
fundamental as oxygenation, circulatory 
stability and neurological assessment are 
determinant factors in therapeutical 
decision-making. Invasive blood-
pressure monitoring, 
plethysmographic pulse-oximetry 
(POX), ECG monitoring, urinary 
output and neurological valuation are 
minimum monitoring standards even 
during transport to tertiary 
(neurosurgical) therapy centres. 
Systolic arterial pressure should be 
kept under 180 mmHg, but should 
not be lowered to more than to a 
mean arterial pressure (MAP) of 90 
mmHg. (Steiner et al., 2013). 
Tranexamic acid (Cyklokapron i.v. 
1g three times daily), a fibrinolysis inhibitor 
is recommended in our centre as a 
pharmacologic re-bleeding prophylaxis, 
given directly after the diagnosis is 
established. (Hillman et al., 2002) This 
treatment is continued until the aneurysm is 
secured.  
The efforts of re-bleeding prevention 
continue in the neurosurgical department, 
where the aneurysm is mapped with DSA 
and a 3D image reconstruction is created. 
After a discussion between the neurosurgeon 
and the interventional neuroradiologist, a 
joint decision is made how to secure the 
aneurysm. 
1. Surgical clipping 
 One of the options is to use an intraoperative 
method, involving an open craniotomy and 
surgical exploration of the aneurysm. It is a 
major neurosurgical operation when a special 
clip, first used by Walter Dandy at the Johns 
Hopkins Hospital in Baltimore, 1937 and 
Figure 7. Titanium surgical Sugita clips for different aneurysm 
applications 
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3. Cerebral infarction (CI) 
CI is defined as radiological (CT, MRI) signs 
of infarction within 6 weeks after an aSAH, 
the latest CT prior to death (in 6 weeks) or an 
autopsy verified infarction. These signs 
should not be directly connected to operation 
or embolisation. These radiological signs 
though must not be present within 48 hours 
of the bleeding (Vergouwen et al., 2010). To 
be more confusing, in American literature 
this could be named as DCI, in contrast to 
older infarction or infarction directly related 
to treatment (post-operative or post-
embolisation complication). It is 
understandable, that review articles and 
meta-analyses have problems defining the 
end-points of the studies. 
Apart from an active neurosurgical 
management and optimised neuro-intensive 
care, the only drug which is documented to 
improve outcome is nimodipin. This is the 
reason why all aSAH patients receive iv. or 
oral nimodipin, during 10-14 days after the 
bleeding.   
 
II. Neurological, 
radiological assessment 
A. Admission assessment 
1. Hunt and Hess scale 
SAH patients’ early evaluation has been 
advocated from the early 1950’s (Norlen and 
Olivecrona, 
1953) and a 
classification has 
been 
systematically 
used since 
Botterell 
published his 
article on 
assessment of the 
perioperative risk 
of SAH patients. 
(Botterell et al., 1956) From his five-grade 
scale evolved the most used SAH grading 
scale developed by William Hunt and Robert 
Hess from Ohio and was the standard 
assessment instrument for half a century. 
(Table 1) (Hunt and Hess, 1968). As it has 
been used world-wide and extensively 
validated, we have chosen this instrument in 
Table 1.  Hunt and Hess grading scale and expected rate of survival at the time of 
publishing(Hunt and Hess, 1968)  
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intensive care with respiratory and 
circulatory support in addition to fluid and 
electrolyte management, but their 
aneurysm(s) are left untreated. 
D. Complications 
The complications after aSAH can be divided 
into early and late ones. The collective name 
for the early complications is “early brain 
injury”, and it occurs within the first 72 hours 
after the haemorrhage. It is a direct result of 
the bleed and has a strong association with 
the amount of extravasated blood and the 
initial rise of intra cranial pressure (ICP). 
Some of the potential mechanisms are 
discussed in a recent article (Rowland et al., 
2012) and characterised as mechanical 
(constriction from bleed, cisternal blood, 
hydrocephalus), physiological (elevated ICP, 
reduced CPP, impaired cerebral 
autoregulation, vasoconstriction),  ionic 
(cortical spreading depression, impaired Ca2+ 
homeostasis,  K+ efflux, Mg2+ disturbance), 
inflammatory (NO-synthetase activation, 
endothelin-1 release, oxidative stress, platelet 
activation) and cell death derived (apoptosis 
and necrosis of endothelium, neurons, 
astrocytes). Although these mechanisms have 
started before the late complications occur, it 
is reasonable to think that they have an 
impact on the likelihood and severity of these 
late difficulties. 
1. Cerebral vasospasm (CVS) 
CVS in the literature denotes radiological 
vasospasm and it includes Trans-Cranial 
Doppler (TCD) identified vasospasm as well, 
which is a common way of following this 
complication in the ICU. It also comprises 
naturally angiography-verified vasospasm 
with CTA, MRA or DSA. As CVS, has been 
associated with late neurological 
complications, it is a frequently used marker 
in genetic and biochemical signal studies. 
2. Delayed cerebral ischemia 
(DCI) 
Recently, a multidisciplinary research group 
defined this entity (Vergouwen et al., 2010), 
as there has been a great confusion in the 
definition and characterisation of this 
important complication. In American 
literature, one might find it as Delayed 
Ischemic Neurological Deficit (DIND) (Lai 
and Du, 2015). It covers focal neurological 
impairment or a decrease of at least 2 points 
in consciousness measured by Glasgow 
Coma Scale (GCS). It is an extremely 
important complication, as DCI is the most 
prominent cause of mortality between 
postictal day 3 and day 14. (Rowland et al., 
2012) The majority of the above mentioned 
“early brain injury” mechanisms have been 
claimed to play a role in this deleterious 
complication. 
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3. Cerebral infarction (CI) 
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been 
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published his 
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perioperative risk 
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been used world-wide and extensively 
validated, we have chosen this instrument in 
Table 1.  Hunt and Hess grading scale and expected rate of survival at the time of 
publishing(Hunt and Hess, 1968)  
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accepted scale for initial neurological 
evaluation of SAH patients. (Teasdale et al., 
1988) They adapted their scale to an already 
established responsiveness assessment scale, 
the GCS and added the existence or absence 
of major focal deficit. They finally agreed on 
a 5 graded scale with a combination of these 
factors (Table 4). A problem 
arose however, when patients 
presented with different levels on 
different axis of the scale i.e. 
intact cortical function but major 
focal deficit. Patients in those 
cases received the worse of 
grades. This is one of the reasons 
why several modifications of 
WFNS scale have emerged 
recently (Sano et al., 2015; Naval 
et al., 2014). 
5. The Fisher scale 
As radiological diagnostics of 
suspected SAH in patients became 
more important, Fisher realised the 
significance of a validated scale 
based on the distribution of blood 
visualised on the initial CT 
examination (Fisher et al., 1980). 
The scale was originally intended to 
help predicting those patients at risk 
for cerebral vasospasm, but it was 
early connected to outcome 
(Gilsbach et al., 1988)(Table 5). 
There are several limitations of this 
4 grade-scale; i.e. it does not differentiate 
between intra-ventricular and intra-
parenchymal blood, it is a blunt instrument 
with only 3 grades where blood at is all 
visible and there is temporal course of the 
blood distribution in the 
Table 4. World Federation of Neurological Surgeons scale for 
assessment of subarachnoid patients (Teasdale et al., 1988) 
Table 5. The Fisher scale for radiological evaluating subarachnoid 
haemorrhage on CT scan 
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most of our papers for assessing SAH 
severity at admission.  
2. Glasgow Coma Scale (GCS) 
As different kinds of neurological 
emergencies started to be admitted to 
dedicated Emergency Units, Teasdale and 
Jennett have realised the importance of an 
aetiology-independent  grading scale 
(Teasdale and Jennett, 1974) and introduced 
a behavioural assessment grading based on 
the best motor, verbal response and eye 
opening, awarding points for each activity. 
The total sum of the points, (max.: 15, min.: 
3) provide the GCS. (Table 2) This scale has 
since then been used for assessment of 
altered consciousness of all possible causes 
in the emergency departments. 
3. Reaction Level Scale 85 
(RLS85) 
In the Nordic countries and especially in 
Sweden, an easier-to-use 8 graded motor 
responsive scale has gained popularity. 
(Starmark et al., 1988) Grades 1-3 describe 
conscious patients, while in Grades 4-8, the 
patients are unconscious. This grading is 
widely used in prehospital and primary 
trauma/neuro-emergency assessment. (Table 
3.) 
4. World 
Federation of Neurological 
Surgeons scale (WFNS) 
Having experienced the 
shortcomings of the Hunt and 
Hess scale a task force within the 
largest community of 
neurosurgeons worked for years 
to establish a more user friendly, 
practical, validated and widely 
Table 3 Glasgow Coma scale for assessment of consciousness and 
responsiveness (Teasdale and Jennett, 1974) 
Table 2. Reaction Level Scale 85 a responsiveness grading for 
fast neurological assessment. (after Starmark, Stålhammar 
et.al) 
13
13 
 
accepted scale for initial neurological 
evaluation of SAH patients. (Teasdale et al., 
1988) They adapted their scale to an already 
established responsiveness assessment scale, 
the GCS and added the existence or absence 
of major focal deficit. They finally agreed on 
a 5 graded scale with a combination of these 
factors (Table 4). A problem 
arose however, when patients 
presented with different levels on 
different axis of the scale i.e. 
intact cortical function but major 
focal deficit. Patients in those 
cases received the worse of 
grades. This is one of the reasons 
why several modifications of 
WFNS scale have emerged 
recently (Sano et al., 2015; Naval 
et al., 2014). 
5. The Fisher scale 
As radiological diagnostics of 
suspected SAH in patients became 
more important, Fisher realised the 
significance of a validated scale 
based on the distribution of blood 
visualised on the initial CT 
examination (Fisher et al., 1980). 
The scale was originally intended to 
help predicting those patients at risk 
for cerebral vasospasm, but it was 
early connected to outcome 
(Gilsbach et al., 1988)(Table 5). 
There are several limitations of this 
4 grade-scale; i.e. it does not differentiate 
between intra-ventricular and intra-
parenchymal blood, it is a blunt instrument 
with only 3 grades where blood at is all 
visible and there is temporal course of the 
blood distribution in the 
Table 4. World Federation of Neurological Surgeons scale for 
assessment of subarachnoid patients (Teasdale et al., 1988) 
Table 5. The Fisher scale for radiological evaluating subarachnoid 
haemorrhage on CT scan 
12 
 
most of our papers for assessing SAH 
severity at admission.  
2. Glasgow Coma Scale (GCS) 
As different kinds of neurological 
emergencies started to be admitted to 
dedicated Emergency Units, Teasdale and 
Jennett have realised the importance of an 
aetiology-independent  grading scale 
(Teasdale and Jennett, 1974) and introduced 
a behavioural assessment grading based on 
the best motor, verbal response and eye 
opening, awarding points for each activity. 
The total sum of the points, (max.: 15, min.: 
3) provide the GCS. (Table 2) This scale has 
since then been used for assessment of 
altered consciousness of all possible causes 
in the emergency departments. 
3. Reaction Level Scale 85 
(RLS85) 
In the Nordic countries and especially in 
Sweden, an easier-to-use 8 graded motor 
responsive scale has gained popularity. 
(Starmark et al., 1988) Grades 1-3 describe 
conscious patients, while in Grades 4-8, the 
patients are unconscious. This grading is 
widely used in prehospital and primary 
trauma/neuro-emergency assessment. (Table 
3.) 
4. World 
Federation of Neurological 
Surgeons scale (WFNS) 
Having experienced the 
shortcomings of the Hunt and 
Hess scale a task force within the 
largest community of 
neurosurgeons worked for years 
to establish a more user friendly, 
practical, validated and widely 
Table 3 Glasgow Coma scale for assessment of consciousness and 
responsiveness (Teasdale and Jennett, 1974) 
Table 2. Reaction Level Scale 85 a responsiveness grading for 
fast neurological assessment. (after Starmark, Stålhammar 
et.al) 
14
15 
 
to a category on a 5 or in the extended 
version (GOSE) 8 hierarchical categories 
during an interview (Teasdale and Jennett, 
1974). This relatively easy-to-use scale gives 
a general index of overall outcome and it 
reflects disability, rather than impairment 
compared to pre-morbid status; i.e. how the 
handicap affects functioning in major areas 
of life (Table 6). It allows comparison 
between different patient-groups (Marschall, 
1987) and been suggested as a measure of 
outcome in clinical trials (Clifton et al., 
1992). The questions are based on the areas 
of everyday life e.g. independence at home, 
independence outside home, employability, 
engaging in pre-morbid social and leisure 
activity and interpersonal relationship 
(Jennett et al., 1981). If inter-observer 
variability is to be kept at minimum a 
structured questionnaire-based interview with 
few, educated raters have to be employed 
(Wilson et al., 1998). We used the 
questionnaire for the extended GOS (GOSE) 
to allow a wider differentiation of the data.   
Table 7. National Institute of Health Stroke Scale (NIHSS), instrument to measure focal neurological deficit 
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subarachnoid/cisternal/intra-ventricular 
space, thereby a time-limit should be set for 
this grading. Similar criticism and a demand 
for new scales came up in the early 2000s 
(Smith et al., 2005) and led to different 
modifications of the original Fisher scale 
(Claassen et al., 2001; Frontera et al., 2006). 
As these revised scales were not available at 
the time of study-design, we employed the 
original, which was nevertheless a validated, 
widely-used assessment-method. 
B. Outcome assessment 
The strength of the present studies and our 
project lies in the outcome assessment. We 
planned for long-term follow up, which we 
considered as a minimum of one year. We 
hypothesized, what later research 
strengthened (Wilson et al., 2013) that a 
substantial recovery may occur 
beyond the usual follow-up 
period of 3 - 6 months. At the 
time of our study design, there 
were not many large aSAH 
patient -groups, that were 
followed over such long period 
without patient loss. 
Furthermore, we have utilised the 
most sophisticated grading scales 
available at the time and tried to 
capture all aspects of a possible 
handicap i.e. global, focal 
neurological, psychological 
dysfunctions and functioning in daily life. As 
recommended  (Anderson et al., 1993), we 
had to choose an outcome investigator not 
involved in the patients’ care. As these 
complex scaling systems required a 
neurological specialist to examine the 
patients and our intention to minimise the 
inter-examiner variability ensued that only 
one neurologist performed all the follow-up 
examinations.  My never fading gratitude 
goes to my co-author and co-worker, Karin 
Nylén MD, PhD for this demanding task. I 
give bellow a brief summary of the scaling 
instruments utilised. 
1. Glasgow Outcome Scales 
(GOS, GOSE) 
GOS is the most widely used outcome 
evaluation tool, where patients are allocated 
Table 6. Glasgow Outcome Scale (GOS) and its extended variant (GOSE) for 
outcome assessment 
15
15 
 
to a category on a 5 or in the extended 
version (GOSE) 8 hierarchical categories 
during an interview (Teasdale and Jennett, 
1974). This relatively easy-to-use scale gives 
a general index of overall outcome and it 
reflects disability, rather than impairment 
compared to pre-morbid status; i.e. how the 
handicap affects functioning in major areas 
of life (Table 6). It allows comparison 
between different patient-groups (Marschall, 
1987) and been suggested as a measure of 
outcome in clinical trials (Clifton et al., 
1992). The questions are based on the areas 
of everyday life e.g. independence at home, 
independence outside home, employability, 
engaging in pre-morbid social and leisure 
activity and interpersonal relationship 
(Jennett et al., 1981). If inter-observer 
variability is to be kept at minimum a 
structured questionnaire-based interview with 
few, educated raters have to be employed 
(Wilson et al., 1998). We used the 
questionnaire for the extended GOS (GOSE) 
to allow a wider differentiation of the data.   
Table 7. National Institute of Health Stroke Scale (NIHSS), instrument to measure focal neurological deficit 
14 
 
subarachnoid/cisternal/intra-ventricular 
space, thereby a time-limit should be set for 
this grading. Similar criticism and a demand 
for new scales came up in the early 2000s 
(Smith et al., 2005) and led to different 
modifications of the original Fisher scale 
(Claassen et al., 2001; Frontera et al., 2006). 
As these revised scales were not available at 
the time of study-design, we employed the 
original, which was nevertheless a validated, 
widely-used assessment-method. 
B. Outcome assessment 
The strength of the present studies and our 
project lies in the outcome assessment. We 
planned for long-term follow up, which we 
considered as a minimum of one year. We 
hypothesized, what later research 
strengthened (Wilson et al., 2013) that a 
substantial recovery may occur 
beyond the usual follow-up 
period of 3 - 6 months. At the 
time of our study design, there 
were not many large aSAH 
patient -groups, that were 
followed over such long period 
without patient loss. 
Furthermore, we have utilised the 
most sophisticated grading scales 
available at the time and tried to 
capture all aspects of a possible 
handicap i.e. global, focal 
neurological, psychological 
dysfunctions and functioning in daily life. As 
recommended  (Anderson et al., 1993), we 
had to choose an outcome investigator not 
involved in the patients’ care. As these 
complex scaling systems required a 
neurological specialist to examine the 
patients and our intention to minimise the 
inter-examiner variability ensued that only 
one neurologist performed all the follow-up 
examinations.  My never fading gratitude 
goes to my co-author and co-worker, Karin 
Nylén MD, PhD for this demanding task. I 
give bellow a brief summary of the scaling 
instruments utilised. 
1. Glasgow Outcome Scales 
(GOS, GOSE) 
GOS is the most widely used outcome 
evaluation tool, where patients are allocated 
Table 6. Glasgow Outcome Scale (GOS) and its extended variant (GOSE) for 
outcome assessment 
16
17 
 
C. Physiological parameters 
To keep physiological parameters within 
normal limits is important in any disease’s 
therapeutical regime, notwithstanding it is 
even more important in aSAH, when the 
central coordination of the different 
mechanisms is failing.  Comprehensive 
therapeutical guidelines for the management 
of SAH patients in the Neurointensive Care 
setting were published a few years ago 
(Wartenberg, 2011; Smith, 2007) 
summarising the main 
aspects of the treatment 
protocols. I describe our 
intensions regarding the 
physiological limits, at 
the time our study-
patients were treated in 
the NICU, Sahlgrenska 
University Hospital.  
Haemoglobin >120 g/l, 
S-sodium >135<150 
mmol/l, S-potassium 4.0-5.0 mmol/l, S-
albumin 35-50 g/l, core temperature 37 ± 0.5 
° C, MABP between 70-100 mmHg, 
intracranial pressure (ICP) <20 mmHg, 
Cerebral perfusion pressure (CPP = MABP-
ICP) >60 mmHg, pO2 12-18 kPa, pCO2 ca 
4.5 kPa and normalized pH. Blood glucose 
was kept stringently between 4-6 mmol/l. 
  
III. Genetic 
neuromarkers 
1. Apolipoprotein E (ApoE) 
Apolipoprotein E (ApoE) is the protein-part 
of very low density lipoprotein (VLDL) 
group, which are often remnants of 
chylomicrons. The protein is only 299 
amino-acid long and circulates in blood, 
cerebrospinal fluid (CSF) and central nervous 
system (CNS) tissue interstitial fluid (Fig.9). 
In the CNS, it is produced by the astrocytes 
and one of its functions is to transport 
cholesterol and other lipids through 
membranes, thereby ApoE is directly 
responsible for the clearance of plasma 
lipoproteins from the cell. The mechanism is 
that ApoE serves as a critical ligand to low 
density lipoprotein receptors. This function, 
to redistribute lipoproteins into the cells is 
Figure 9. Apolipoprotein E3 and E4’s 3D structure. Note the difference in mobility of 
the arm, and thence difference in function! With permission. (Mahley and Huang, 2012) 
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Stroke Scale (NIHSS) 
NIHSS is a focal neurological deficit 
assessment scale which was developed by 
Brott and co-workers (Brott et al., 1989) to 
document impairment after a stroke, It has 
been widely accepted as a study instrument, 
and is 
recommended 
by the 
American 
Heart 
Association for 
outcome 
classification 
even in clinical 
use. It assigns 
points for focal 
neurological 
deficits on an 
increasing 
scale in the 
areas of 
language, 
speech, 
coordination, 
visual field, 
neglect, eye-movement, consciousness and 
motor- and sensory functions (Table 7). 
3. The Barthel Index 
The Barthel index is a measure of 
independence in 10 important activities of 
daily living (Table 8). It has been a valuable 
instrument to estimate the amount of 
assistance a person requires after an illness or 
injury. It was initially designed to monitor 
improvement after treatment in patients with 
chronic neurological diseases (Mahoney and 
Barthel, 1965). It measures the functional 
capacity in eating, bathing, dressing, walking 
and getting out of bed and chair. The points 
in the index give a good estimate on how 
much nursing assistance a person requires. 
On the contrary, patients achieving full credit 
in the Index, are not necessarily capable of 
living an independent life.   
 
Table 8. The Barthel Index. Assessing Activities of Daily Living (ADL), a measure of independence 
2. National Institute of Health 
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is 4.5-time-increase of risk 
compared to the general population. 
(Ronkainen et al., 1997)  
These family-linkage studies and 
large genome-wide association 
studies (GWAS) identifying a locus 
on the 9th chromosome’s short arm 
(9p21) as risk area for IA (Bilguvar 
et al., 2008) and even other blood-
vessel related anomalies, like 
coronary artery disease (CAD), 
aortic aneurysm, and arterial 
stiffness encouraged further investigation in 
the region to search for the responsible 
genetic variant (Fig.10). As no causative 
genotype had been identified on this location 
at that time, we had to further narrow down 
the pursuit to single nucleotide 
polymorphisms (SNPs) – one single base-
pair interchanges, which are the most 
frequent occurring genetic alterations. We 
have investigated in Paper III, if any of the 
identified SNPs correlate to ruptured IAs 
independently from other risk factors.  
 
 
IV. Biochemical 
neuromarkers 
1. C-Reactive Protein (CRP) 
CRP was discovered by Tillett and acquired 
its name from a reaction with the C-
polysaccharide of Pneumococcus (Tillett and 
Francis, 1930). It is one of the body’s most 
important acute-phase proteins mainly 
synthesised in the liver. It responds to 
cytokines, mainly IL-6, secreted by 
macrophages, T-cells and also adipocytes. It 
has an annular form and belongs among the 
pentameric proteins, which are common as 
ionic-channel receptors or viral capsids. They 
can form a channel, expressing receptors and 
with their ligand attached, they often undergo 
a conformational change, thereby interacting 
with the molecule (often neutralising, or 
facilitating transport). It conforms to its 
putative roll to detoxify and neutralise 
harmful substances escaping into the 
circulation (Fig.11). 
As an acute-phase protein, CRP’s 
concentration rises quickly and can increase 
well over 1000-fold and peaks around 48 h 
after the insult and returns to base-line after 
Figure 10. C-Reactive Protein with its 5 sub-units organised in an 
annular, pentameric form. (Public domain) 
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fundamental for cellular reparatory processes 
(Mahley and Huang, 2012). 
The protein is coded by a single gene locus 
on the 19th chromosome’s short arm 
(19q13.2) and there are three different alleles 
(ε2, ε3, ε4,) encoding three different 
isoforms of the protein (E2, E3, E4) with 
profoundly different form and function. 
(Mahley, 1988)  
ApoE was early associated with Alzheimer 
disease (Mahley, 1988; Blennow and 
Cowburn, 1996; Strittmatter et al., 1993), 
and this was the start of an intensive research 
on its neuro-pathological effect. Kim has 
reviewed some of these known mechanisms 
(Kim et al., 2009); impaired neurite 
outgrowth, cytoskeletal disruption, 
mitochondrial dysfunction, impaired 
synaptogenesis, amyloid (Aβ) production, 
altered clearance and deposition, lysosomal 
leakage and apoptosis and finally impaired 
learning in rodents. The discovery of these 
detrimental effects led to further research 
within all possible neurological disorders, 
among which traumatic brain injury 
(Helgadottir et al., 2008), multiple sclerosis 
(Fazekas et al., 2001), stroke and 
intracerebral haemorrhage (McCarron et al., 
1999), fronto-temporal dementia (Agosta et 
al., 2009) and Parkinson disease (Martinez et 
al., 2005) are found to be negatively affected 
by the presence of ApoE4.  
SAH patients have also been investigated for 
ApoE effect, but the results have been rather 
incongruent. About equally as many have 
found a negative effect of ApoE4 
(Niskakangas et al., 2001; Leung et al., 
2002) as no effect at all (Morris et al., 2004; 
Fontanella et al., 2007). This ambiguity of 
the results and the regional relevance, as 
there is a geographical difference in allele 
distribution in the world, which motivated 
our study II. 
2. Chromosome 9p21  
Genetic association with SAH has been 
recognised for years as it was well known 
that first degree relatives to patients with 
intracranial aneurysm (IA) or SAH have 3-5 
times increased risk to develop the same 
disease. (Gaist et al., 2000) and again in the 
same relatives the risk of harbouring an 
unruptured aneurysm has grown to 9%, that 
Figure 90 Chromosome 9 and segment 9p21’s localisation 
and approx. size. With permission from Leica Microsystems 
AB, Bromma, Sweden. 
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is 4.5-time-increase of risk 
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Figure 10. C-Reactive Protein with its 5 sub-units organised in an 
annular, pentameric form. (Public domain) 
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fundamental for cellular reparatory processes 
(Mahley and Huang, 2012). 
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3. Tumor Necrosis Factor 
Receptor 1 (TNRF1) 
TNFR1, together with TNFR2 are receptors 
for tumour necrosis factor α (TNFα) and 
lymphotoxin α (LTα), both pro-
inflammatory cytokines and they are 
expressed on most cell types in the body. 
TNFα and LTα play a major role in immune 
regulation and in host-defence reactions.  
They are expressed mainly by macrophages 
after cell injury or inflammation but other 
haematopoietic or non-hematopoietic cell-
types can be involved. (Probert et al., 2000) 
TNFα is responsible for recruitment of 
leucocytes to inflammation area and 
regulates cell-death by proliferation, 
cytotoxicity and apoptosis. (Wallach et al., 
1997) The majority of biological response to 
TNFα manifests through TNFR1 receptors, 
while TNFR2 has some special functions. It 
mediates tymocyte proliferation and certain 
suppression of inflammatory processes 
(Peschon et al., 1998). TNFR1 receptor 
mediates endotoxin shock and overexpressed 
TNFα/ LTα or TNRF1 is detrimental, 
resulting in rheumatoid arthritis or multiple 
sclerosis. TNFα/ LTα’s pro-inflammatory 
properties demonstrate local inflammation in 
transgenic mice and their cytotoxic effects 
can trigger apoptosis and cell-death in 
oligodendrocytes. (Selmaj and Raine, 1988).  
TNFα studies are however contradictory and 
it may depend on the short half-life of this 
cytokine, and that it can bind to undetectable 
complexes (Beutler et al., 1985). It has been 
suggested that the soluble forms of TNFR1 
and 2 with their longer half-life are more 
reliable indicator of the TNF system 
activation than the short-lived cytokine itself 
(Kreuzer et al., 1996). Moreover the soluble 
TNFR1 can be viewed as an independent 
inflammation marker as its transition to 
soluble isomer is a complex activity, 
dependent on other inflammatory 
mechanisms (Diez-Ruiz et al., 1995). 
4. Neutrophil Gelatinase 
Associated Lipocalin (NGAL) 
NGAL or Lipocalin-2 is a 25 kDa 
glycoprotein and has its principal function in 
innate immunity where it concentrates and 
sequesters iron in the form of siderophores. 
This defence mechanism is pivotal in 
bacterial protection (Yang et al., 2002). It 
was first described in neutrophils, but now 
nearly all other cell-types have been shown 
to express NGAL under different 
circumstances e.g. in the brain under 
oxidative stress (Naude et al., 2012).  
It is widely used as marker for acute kidney 
injury and a general inflammation signalling 
substance. During inflammatory processes 
the expression of NGAL is altered i.e. in 
meningitis, myocarditis, psoriasis, 
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7-12 days if the stimulus is removed 
(Rothoerl et al., 2006). It is cleared from 
plasma monoexponentially, independent of 
concentration with a half-life of ~19 h and it 
makes the production the only determinant of 
its level. This makes CRP a perfect marker of 
inflammatory activity in the body.  
Numerous publications have connected SAH 
to inflammatory mechanisms (Rothoerl et al., 
2006; Bhardwaj, 2003; Juvela et al., 2012), 
but all of them included surgically treated 
SAH patients, thereby clouding the 
inflammatory mechanisms caused by SAH 
with the one induced by a craniotomy 
(Mirzayan et al., 2007). It was plausible to 
think that merely endovascularly treated 
patients’ CRP response would have a closer 
relationship to the haemorrhage and therefore 
the outcome. We explored this hypothesis in 
Paper I and we returned to CRP in Paper IV. 
The biomarkers listed below were included 
in the Neuropanel biochip array we tested in 
SAH patients in Paper IV. 
2. Interleukin 6 (IL-6) 
Interleukin 6 is a pro-inflammatory cytokine 
(secreted protein, signal molecule) and it is 
one of the founding members of a now-a-
days rather large group of interleukins which 
were named after being described first in 
leucocytes. They are glycoproteins by 
chemical nature, consisting of 170-180 
amino-acids and show a quadruple helix 
bundle structure. Prior to a consensus 
meeting in Switzerland in 1979, it was called 
B-cell stimulatory factor 2 (BSF2) or 
Interferon β2 because of its first described 
effect on B-cells’ differentiation to 
immunoglobulin secreting cells. Besides this 
immunogenic effect, IL-6 is now accepted as 
neuropoietin (Erta et al., 2012) consequent to 
its neuro-protective and neuron 
differentiating effect. It has an important role 
as acute-phase reactant from hepatocytes, 
acting as primary activator of CRP. IL-6 is 
activated in infectious and inflammatory 
diseases, autoimmune processes, in diabetes, 
atherosclerosis, depression, Alzheimer -
disease, rheumatoid arthritis and many other 
conditions. It is produced in macrophages, 
Th2 cells, B-cells, astrocytes, microglia, 
neurons, endothelium and hepatocytes. The 
major neuro-protective effect comes from its 
attribute that it inhibits TNFα and IL-1β via 
activating IL-1ra and IL-10. IL-6 also 
contributes to neuro-regeneration by 
promoting neuro-remodelling, and 
angiogenesis (Gertz et al., 2012). Finally, it 
has to be mentioned, that IL-6 is the main 
regulator of fever in the acute-phase response 
by crossing the blood-brain barrier and 
promoting prostaglandin E2 synthesis in 
hypothalamus thus changing the body 
temperature.  
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and depression. The serum levels are 
normally undetectable if not an immense 
disruption of BBB occurs e.g. SAH, cerebral 
trauma, intra or cerebral haemorrhage 
(Mayer et al., 2013). In that case the 
concentration is closely associated with the 
injury size (Nylen et al., 2007; Nylen et al., 
2006; Nylen, 2007). 
6. Brain-Derived Neutrophic 
Factor (BDNF) 
BDNF is a signal protein and one of the most 
prominent members of the neurotrophins or 
nerve growth factors. Its closest relatives in 
this family are the neurotrophins 3 and 4 and 
nerve growth factor (NGF). It is synthesised 
in the endoplasmic reticulum and passed on 
into vesicles in the brain and the periphery, 
like in retina, kidneys saliva and the prostate. 
It acts on the neurons, promoting neuronal 
survival, neurogenesis and synaptogenesis. 
(Lu, 2003) In animal studies it reduces 
ischemic injury and improves recovery and 
post-injury regeneration (Almeida et al., 
2005). 
BDNF is most active in the cortex, 
hippocampus, basal ganglia and areas, where 
learning, memory and higher thinking take 
place. It may work even in adult brain 
through neural stem-cells, by promoting 
neuroneogenesis (Pencea et al., 2001). In 
knock-out mice, it produces severe brain 
developmental defects and even perinatal 
death. This emphasises the importance of this 
neurotrophin in the embryonal brain 
formation and neuronal growth. Normal 
serum level was reported round 30 ng/ml and 
low values were considered around half that 
level. It is easy to understand why this 
neuromarker is included in a neuropanel-
array. 
7. Fatty-Acid Binding Protein 
(FABP) 
Lipids, where fatty-acids, eicosanoids and 
retinoids are included function not only as 
fuel source, building-blocks to membranes 
and cellular structures, but also as intra- and 
extra-cellular signalling substances. Recent 
studies, summarised in a review 
(Hotamisligil and Bernlohr, 2015), enlighten 
us that lipids take part (i) in modifying the 
actions and locations of proteins, such as 
kinases or ion-channels; (ii) signal through 
proteins to cell surface or between cells as G-
protein; (iii) ligand for transcription factors, 
modifying expressions of other regulators; 
(iv) regulate hormone actions, like PI3K, and 
NFκβK pathways and finally (v)  pattern 
recognition receptors.  
The insolubility and toxic effects of the free 
forms of these molecules, require, however a 
type of non-catalytic binding-protein e.g. 
FABPs. The original FABP was described in 
small intestine as a 12 kDa  intracellular 
protein (Ockner et al., 1972) but since then 
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rheumatoid arthritis. The serum level of 
NGAL is considered low below 20 ng/ml, 
medium round 200 ng/ml and high above 
1200 mg/ml. Apart from renal injury 
detection and delayed graft dysfunction 
(Shapiro et al., 2010), it has been shown to 
predict septic shock (AUC:0.77), and death 
(AUC:0.79) among SIRS patients in the ICU, 
especially together with IL-1 and Protein-C. 
The cut off level was 48 ng/ml (Endre et al., 
2011). Further, it was found useful in heart 
failure, epithelial malignancies and even in 
late-life depression (Naude et al., 2013). The 
proposed mechanism of NGAL in the CNS 
encompasses cellular-stress via increased 
expression of NGAL, leading to microglia 
activation, astrogliosis and neuronal 
apoptosis, resulting in behavioural changes 
(Gouweleeuw et al., 2015). These properties 
qualify NGAL to be included into a cerebral 
injury-marker panel (Paper IV). 
5. Glial Fibrillary Acidic 
Protein (GFAP) 
GFAP is a type III intermediary 
filament, with an average diameter 
of 10nm (Fig.12). It is found in glial 
cells in the CNS and is responsible 
for the cytoskeletal structure of 
astrocytes, helping to maintain their 
mechanical strength. Apart from 
structural maintenance, GFAP plays 
a role in cell communication and 
even in the functionality of the 
blood-brain barrier (BBB). During mitosis, 
they regulate the filament network in the 
cytoplasm controlling the cell partitioning. In 
astrocyte-neuron interaction, GFAP may 
have a bridging role through the glymphatic 
system and this may also be the way it 
reaches the bloodstream via venous 
adjunctions or when BBB disruption occurs 
(Plog et al., 2015). 
Following brain injury and in some chronic 
diseases the astrocytes respond with an 
unspecific transformation called astrogliosis. 
It is a proliferation, hypertrophy and building 
of abundance of intermediate filaments. The 
severity and time-course varies in this 
transformation from slowly and sporadically 
as in multiple sclerosis or massive and fast-
progressing, as in fibrinoid leucodystrophy, 
Alexander’s disease.  
If GFAP’s level in the astrocytes is reduced 
(genetic disorders, transcriptions difficulties, 
multifactorial), this may lead to other neuro-
psychiatric syndromes, like schizophrenia 
Figure 11. Glial Fibrillary Acidic Protein (GFAP). Intermediary 
filaments form a quaternary chain. 
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9. D-dimer (DDMR) 
DDMR is fibrin degradation protein (FDP), 
which is a marker of the coagulation system 
activation. The coagulation system can be 
activated by intrinsic (endothelial activation) 
or extrinsic (tissue activating factors via 
Factor VII) pathways and both of them 
interconnect to fibrinogen, which in the 
presence of Ca2+ ions as cofactors and an 
activated thrombin converts to fibrinogen -
polymers and further with the help of a 
thrombin-activated Factor XIII to fibrin clot. 
The activated Factor XIIIa binds a glutamyl - 
lysyl amid crosslink which stabilises the 
blood clot. When the wound heals the 
coagulation stimulus ceases and fibrinolytic 
mechanisms start to take over. The enzyme 
plasmin starts to break down the fibin-clot to 
high molecular-weight polymers and then 
further to small polymers, FDPs. One of 
these FDPs is DDMR.  
 It received its name that fibrinogen’s two D 
domains and one E domain is cross-linked 
together (Fig.13). It is normally undetectable 
in serum and increases rapidly when the 
coagulo-fibrinolytic system is activated, like 
in DIC, thrombosis, DVT, PE, 
and sinus thrombosis. DDMR 
was discovered in 1973 and it 
came to routine use at the end 
of 1990s. It is tested with 
monoclonal antibodies with a 
reference value below 0.5 
mg/L.  
As SAH produces blood-clot 
and microvascular coagulation 
is suggested as causative 
mechanism for DCI, the 
coagulation system is involved in the 
pathological mechanism of the disease. This 
makes DDMR a neuro-marker to 
consecutively analyse.  
Figure 13. Coagulation mechanism and the early fibrinolysis, producing D-dimer 
(Public domain) 
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similar molecules were shown in kidneys, 
adipose-tissue, myocardium, liver and brain. 
Their function were further elucidated and 
revealed that they not only buffer and 
physically transport lipids, but they serve as 
mediators and as communicating agents 
within and between cells and between organs 
thus supporting immunometabolism. In the 
CNS, 4 isoforms are detected B-(brain), H-
(heart), E-(epidermal) and M-(myelin)FABP. 
B-FABP is present mainly in astrocytes, H-
FABP, the most prominent of all FABSs, in 
neurons and finally M-FABP is found in 
peripheral nerves (Pelsers and Glatz, 2005). 
Their role could be demonstrated in all 
metabolic diseases, like diabetes, obesity and 
also in coronary artery disease, inflammatory 
conditions and in the CNS: in stroke, cerebral 
injury and neurodegenerative diseases, like 
Alzheimers and Creutzfeldt-Jakob disease. It 
is a fast-reacting injury marker, and after 2-3 
hours B- & H-FABP rises in serum and stay 
elevated up to 120 hours. The cut-off serum 
concentration for cell injury is 5 - 6 µg/L. 
(Pelsers et al., 2004) 
8. Neuron-Specific Enolase 
(NSE) 
NSE was first discovered in 1965 (Moore 
and McGregor, 1965) as an intracellular 
protein from the brain. Later it was described 
as a 78 kDa large, dimeric isoenzyme to a 
glycolytic enzyme, enolase. NSE can be 
found in the neuron’s cytoplasm; where it 
circulates with axoplasmic transport. (Cheng 
et al., 2014) but normally it is not secreted 
out of the cell. It can appear in CSF and 
thereafter in the serum with neuronal 
damage. It is hardly detectable in healthy 
individuals but increasing rapidly with neural 
disruption. This quality makes it theoretically 
an ideal neuronal injury marker, explaining 
why it has been investigated intensively. 
Gradisek recommended it as prognostic 
biomarker and therapeutic indicator after 
traumatic brain injury. (Gradisek et al., 2012; 
Olivecrona and Koskinen, 2012)  
Recent meta-analysis in 16 studies found a 
strong correlation between NSE serum levels 
and outcome or death. (Cheng et al., 2014) 
They found 100 % sensitivity for poor 
outcome and mortality at the levels of 11.6 – 
20 µg/L and > 20 µg/L respectively. NSE 
rises within 12 hours of the neural injury and 
decreases within hours if the neural cell-
disintegration ceases as the protein has a 
half-life of ~ 24 hours. 
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9. D-dimer (DDMR) 
DDMR is fibrin degradation protein (FDP), 
which is a marker of the coagulation system 
activation. The coagulation system can be 
activated by intrinsic (endothelial activation) 
or extrinsic (tissue activating factors via 
Factor VII) pathways and both of them 
interconnect to fibrinogen, which in the 
presence of Ca2+ ions as cofactors and an 
activated thrombin converts to fibrinogen -
polymers and further with the help of a 
thrombin-activated Factor XIII to fibrin clot. 
The activated Factor XIIIa binds a glutamyl - 
lysyl amid crosslink which stabilises the 
blood clot. When the wound heals the 
coagulation stimulus ceases and fibrinolytic 
mechanisms start to take over. The enzyme 
plasmin starts to break down the fibin-clot to 
high molecular-weight polymers and then 
further to small polymers, FDPs. One of 
these FDPs is DDMR.  
 It received its name that fibrinogen’s two D 
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Figure 13. Coagulation mechanism and the early fibrinolysis, producing D-dimer 
(Public domain)
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similar molecules were shown in kidneys,
adipose-tissue, myocardium, liver and brain. 
Their function were further elucidated and
revealed that they not only buffer and
physically transport lipids, but they serve as
mediators and as communicating agents
within and between cells and between organs
thus supporting immunometabolism. In the
CNS, 4 isoforms are detected B-(brain), H-
(heart), E-(epidermal) and M-(myelin)FABP.
B-FABP is present mainly in astrocytes, H-
FABP, the most prominent of all FABSs, in
neurons and finally M-FABP is found in 
peripheral nerves (Pelsers and Glatz, 2005). 
Their role could be demonstrated in all
metabolic diseases, like diabetes, obesity and
also in coronary artery disease, inflammatory
conditions and in the CNS: in stroke, cerebral
injury and neurodegenerative diseases, like
Alzheimers and Creutzfeldt-Jakob disease. It
is a fast-reacting injury marker, and after 2-3 
hours B- & H-FABP rises in serum and stay
elevated up to 120 hours. The cut-off serum
concentration for cell injury is 5 - 6 µg/L.
(Pelsers et al., 2004)
8. Neuron-Specific Enolase
(NSE)
NSE was first discovered in 1965 (Moore
and McGregor, 1965) as an intracellular
protein from the brain. Later it was described
as a 78 kDa large, dimeric isoenzyme to a 
glycolytic enzyme, enolase. NSE can be 
found in the neuron’s cytoplasm; where it
circulates with axoplasmic transport. (Cheng
et al., 2014) but normally it is not secreted
out of the cell. It can appear in CSF and
thereafter in the serum with neuronal
damage. It is hardly detectable in healthy
individuals but increasing rapidly with neural
disruption. This quality makes it theoretically
an ideal neuronal injury marker, explaining 
why it has been investigated intensively.
Gradisek recommended it as prognostic
biomarker and therapeutic indicator after
traumatic brain injury. (Gradisek et al., 2012;
Olivecrona and Koskinen, 2012)
Recent meta-analysis in 16 studies found a
strong correlation between NSE serum levels
and outcome or death. (Cheng et al., 2014)
They found 100 % sensitivity for poor
outcome and mortality at the levels of 11.6 –
20 µg/L and > 20 µg/L respectively. NSE
rises within 12 hours of the neural injury and
decreases within hours if the neural cell-
disintegration ceases as the protein has a
half-life of ~ 24 hours.
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AIMS 
 
In this clinical study on patients with aneurysmal subarachnoid haemorrhage (aSAH) we 
aimed to investigate the following questions: 
 
 To study the development of a well-known inflammatory marker C-reactive protein 
during the early course of the disease and investigate, if these changes can be 
associated to an established complication, cerebral vasospasm and the long-term 
outcome. 
 
 To evaluate if a disadvantageous genetic variation in coding Apolipoprotein E has an 
effect on disease incidence, complication frequency and outcome after aSAH 
 
 
 To elucidate, with the tools of genetics if proposed chromosome region 9p21 contains 
information to predispose for aSAH. 
 
 
 To evaluate a novel investigation method, biochip-array neuropanel’s applicability in 
aSAH patent-monitoring and its potential for outcome prediction. 
 
  
1 
 
PATIENTS AND METHODS 
I. Inclusion 
The study protocol was approved by the 
University Ethics Committee Gothenburg, 
Sweden with the allocation number S 161-00 
and all the studies conformed to the Helsinki 
Declaration on human research.  
All patients were admitted to the 
Neurointensive Care Unit at Sahlgrenska 
University Hospital, Gothenburg, Sweden 
between October 2000 and December 2002. 
They were consecutively considered for 
inclusion in the study if satisfying the 
following criteria: 
i. SAH was seen on CT-scan or 
detected with cerebrospinal fluid 
(CSF) analysis with increased red-
blood-cell count or the detection of 
xanthochromia on CSF 
spectrophotometry.  
ii. The debut of symptoms, typically 
thunderclap headache with altered 
consciousness must have occurred 
within 48 hours of admission, 
although some patients might have 
experienced headaches previously 
(warning headache). 
iii.  After admission, a cerebral 
angiography was performed with CT 
angiography or conventional digital 
subtractions angiography (DSA) with 
3D image reconstruction and the 
intracranial aneurysm/s had to be 
identified in relation to the bleeding. 
iv. The patient had to be permanently 
residing in Sweden for long-term 
outcome follow-up.  
v. Finally an informed consent from the 
patient or next of kin had to be 
obtained within the first week of 
treatment.  
202 patients fulfilled the inclusion criteria 
and were eligible for the studies but for other 
criteria listed beneath different numbers of 
patients were enlisted in the different studies.  
II. Regime 
Already after the diagnosis was established a 
first-physician neurological assessment was 
performed, (RLS, GCS, H&H, WFNS), 
previous and present medical conditions were 
noted, iv. tranexamic acid (Cyclocapron®) 
administered, and intensified monitoring was 
instituted. This involved invasive arterial 
pressure recording and systolic blood 
pressure management, keeping it below 160 
mmHg even during transport from primary or 
secondary health care centres. Securing the 
airways and ventilation were mandatory if 
the patient became unconscious. After 
admittance to the university hospital, the 
patients were treated and observed in the 
intensive care unit, most of them in a 
specialised neuro-intensive care unit (NICU).  
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management.  
 
During the patient treatment venous blood 
samples were collected on days 0, 1, 2, 3, 4, 
6, 8, and between days 10-14. Physiological 
and laboratory parameters were registered 
and any surgical interventions recorded.  
After one year (11-13 month), a complete 
neurological evaluation was performed and 
patient status recorded with GOSE, NIHSS 
and Barthel score by the same neurologist, 
blinded to the investigated 
(biochemical/genetical) markers. The study 
plan is summarised on Table 9. 
III. Data collection and 
analysis  
A. Paper I. (CRP) 
202 patients were considered for inclusion 
with SAH, who were admitted to NICU. The 
following patients were excluded:  3 patients 
were admitted later than day 2 after the 
haemorrhage, in 33 patients, no aneurysm 
was detectable, no angiographic examination 
could be performed in 4 patients and no 
informed consent could be attained or the 
consent withdrawn in 9 cases. As described 
in the introduction craniectomy, as most 
major surgical interventions increase CRP, 
we excluded patients with surgical clipping 
as therapy options (39 patients) and have 
chosen to follow percutaneously treated 
patients. As 3 patients were lost for follow-
up and in 13 patients consecutive data were 
missing for AUC calculation, 98 patients 
remained in this patient selection. The 
patients’ demographics and characteristics at 
admission and during observation can be 
seen in Table 1 in Paper I. 
Data collection routines were described 
above (Table 1). Data analysis was 
performed instantaneously in the hospitals 
accredited laboratory with an 
immunochemical kinetic turbidimetry 
technique on a BH/Hitachi 917 analyser. 
(Roche-Diagnostic, 2001) 
B. Paper II. (APOE) 
196 consecutive SAH patients with APOE 
genetic information available, were 
considered to be included to this genetic 
study and 148 patients remained finally 
enrolled. Of those non-eligible (mostly the 
same as in Paper I), 3 patients were admitted 
later than day 2, no aneurysm was detected in 
33 patients, no informed consent/consent 
withdrawal in 9 cases and finally 4 patients 
lost for long-term outcome. 105 patients 
treated with endovascular technique, in 39 
patients the aneurysm was secured with 
neurosurgical clipping. 4 patients were 
conservatively treated since their clinical 
condition did not permit active intervention.  
221 population-based, healthy individuals 
acted as control cohort, since we had the 
2 
 
Patients were treated according to a 
standardised protocol which entailed 
securing the aneurysm by neurosurgical 
intervention (clipping of the aneurysm) or 
neuroradiological endovascular coiling after 
discussion between neurosurgeon and 
interventional radiologist. In some instances, 
when both therapy options were equally 
appropriate the patients were included in the 
International Subarachnoid Aneurysm Trial 
(ISAT), an international multicentre 
randomised study, where Sahlgrenska 
University Hospital participated between 
1997 and 2002.(Molyneux et al., 2002) In a 
few occasions (3 patients), conservative 
treatment with basic intensive care 
management was the therapy of choice. 
During the patient care the physiological and 
laboratory parameters were kept between 
strictly monitored limits, detailed in the 
Introduction.  
To reduce cerebral vasospasm (CVS), an 
early infusion of nimodipine (Nimotop®), a 
selective calcium antagonist were 
administered 2 mg/h for 10 days. In some 
mild cases, the patients received oral 
nimodipine (60 mg every 4 h) in the last 3 
days.  CVS was monitored with trans-cranial 
Doppler ultrasound (TCD) 3 times weekly or 
daily if spasm was discovered. CVS was 
registered if the peak systolic blood-flow 
velocity increased above 2 m/sec in the 
middle cerebral artery (MCA) or above 1.7 
m/sec and concomitant neurological 
deterioration. The same applied if CVS was 
seen on CT or conventional angiography 
(DSA). These signs needed to lead to 
therapeutical measures i.e. increased 
nimodipine administration, volume therapy 
to counteract spasm or blood pressure 
Table 9 Overview of the study plan. (aSAH - day of haemorrhage, marking means activity) 
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rs1537378 recently found in association with 
ischemic stroke and large vessel disease 
although it was not in the same (linkage 
disequilibrium) LD structure with the others. 
We used TaqMan Custom Assays to 
genotype patients and controls with primers 
and probes specially made at Applied 
Biosystems (Carlsbad, CA, USA). 384 Well 
GeneAmp PCR system 9700 was used for 
amplification and fluorescence imaging was 
carried out on an ABI PRISM 7900HT 
Sequence Detector (both from Applied 
Biosystems). The analyses were blinded to 
patient-control status. One assay, rs1333040 
had technical problems and could not be 
repeated. The 5 successfully genotyped SNPs 
tagged 90% of the SNPs in HapMap in the 
9p21’s region of interest. 
D. Paper IV (Neuropanel) 
The aim of this study was to evaluate a novel 
neuromarker biochip array and to test if the 
course of the 9 markers in the array can be 
associated to initial neurological condition 
measured with Hunt and Hess scale (H&H), 
cerebral vasospasm (CVS) during the first 
two weeks or long-term general outcome 
measured with the Extended Glasgow 
Outcome Scale (GOSE), the focal 
neurological deficit with the National 
Institute of Health Stroke Scale (NIHSS) and 
their activity of daily living with the Barthel 
Index score. We wanted to assess if the 
markers individually or together could 
predict any of these parameters during the 
course of aSAH. 
We aimed to select randomly approximately 
40 patients equally distributed among the 
H&H categories (H&H 1-5) with full set of 
blood samples (see above). 41 patients were 
recruited and their demographics, disease, 
therapy, complication and outcome attributes 
are presented in Table 10.  
In the next subchapter I describe the clinical 
scales utilised and how we dichotomise them 
for easier clinical interpretation. 
We tested the selected series of serum 
samples for the putative brain damage 
markers’ concentration (GFAP, IL6, CRP, 
NGAL, NSE, BDNF and DDMR) in a 
biochip array cerebral panel (Randox, 
Crumlin, UK). It is a semi-automated system, 
where the array is a solid substrate, 
containing the immobilised specific 
antibodies in separate areas for separate 
protein markers. The technique is designed to 
simultaneously quantify the different 
substrates in a drop (35-100 µl) of serum, 
plasma or cerebrospinal fluid. The analyses 
were performed blinded for the clinical data.  
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intention to study the variant allele’s effect 
on the incidence of aSAH. These healthy 
individuals were recruited from controls to 
other studies from the same geographical 
area (Blennow et al., 2000; Prince et al., 
2004). 
We collected blood at admission from the 
patients for genetic examination and at 
samplings’ occasion from the controls (Table 
1, Paper II). Genomic DNA was extracted 
from the samples with Geno-Prep kit 
(Genolution Pharmaceuticals Inc. Seoul, 
Korea) and GenoM-48 DNA purification 
system (GenoVision VmbH, Vienna, 
Austria), which is a magnetic particle-based 
technology. The solid phase for capturing 
and purifying nucleic acid (NA) uses 
magnetic stand, magnetic bead and 
chaotropic agents (GTC GuHCl) as lysis and 
binding agents, alcohols as washing and 
water as elution of isolated NAs. (Genolution 
Pharmaceutical, 2015; Blennow et al., 2000). 
Genotypes were obtained using a solid-phase 
minisequencing method as previously 
described (Blennow et al., 2000). 
C. Paper III (9p21) 
183 patients with verified aSAH who were 
admitted to the University hospital were 
enrolled in this genetical study where the 
analysis material was blood-sample drawn 
from the patients on the admission day. Their 
allelic frequencies were compared to 366 
healthy controls, who were recruited from 
population based health survey (Wilhelmsen 
et al., 1997) and the Swedish Population 
Register. These controls were matched for 
age, sex and geographical area. As 
recognised risk factors for SAH, 
hypertension and current or previous 
smoking habits were noted. As described in 
the Introduction the region 21 on 
chromosome 9p is recognised to show an 
association with intracranial aneurysms (IA) 
in a large GWAS on different populations 
(Bilguvar et al., 2008) and also in a candidate 
gene study (Helgadottir et al., 2008). 
Additionally more cardiovascular diseases 
were associated to this region like aortic 
aneurysm, coronary artery disease, arterial 
stiffness and also ischemic stroke. As 
different vascular properties are connected to 
this area (Wellcome Trust Case Control, 
2007) it became interesting for susceptibility 
for intracranial vascular weakness, thereby 
aneurysm formation. 
A 44 kbp (kilo base-pair) region was tagged 
by using HapMap Central European (CEU) 
genetical data and Haploview 4.1 program 
(Broad Institute; Cambridge, MA, USA). 
This tagging with r2=0.8 and minor allele 
frequency (MAF) of 0.1, resulted in six 
single-nucleotide polymorphisms (SNPs): 
rs10965227, rs1547705, rs7857345, 
rs1333045, rs1333040, and rs10757278. To 
further analyses, we added one extra SNP, 
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outcome evaluation was performed with 
GOSE, NIHSS, and Barthel score.  
Dichotomisation was performed as in Paper 
I. Area and gender matched control group 
with known APOE constitution was 
recruited. 
C. Paper III (9p21) 
Only incidence of aSAH was confirmed and 
genetical variation investigated in a case-
control study. 
D. Paper IV (Neuropanel) 
Hunt and Hess scale was utilised as selection 
criteria and the levels of 9 biochemical 
markers were followed and the course was 
compared to H&H status, the presence or 
absence of CVS and outcome parameters 
with GOSE, NIHSS, and Barthel score. 
V. Statistics 
Statistical analyses were performed with 
SPSS 21.1 (Statistical Packages Software 
System – IBM Corp. Armonk, NY, USA) 
and SAS 9.4 (Statistical Analysis Software – 
SAS Inst. Inc. Cary, NC, USA). In planning 
(i.e. sample size calculation) and result 
interpretation (correct statistics) professional 
statistical expertise was entrusted (Statistiska 
Konsultgruppen, Gothenburg, Sweden). I 
listed the statistical methods, employed in the 
separate papers in the table below. (Tabl. 11)  
Apart from the above mentioned statistical 
methods, one additional genetic statistical 
software was utilised in Paper III in 
conjunction with haplotype frequency 
calculation. The THESIAS Java based 
program is constructed to performed 
Table 11 The applied statistical methods for the individual papers. Abbreviations: ROC, -receiver operator 
characteristic curve, LR, -likelihood ratio, PPV, -positive predictive value 
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IV. Clinical and 
radiological assessment 
The different types of scales, admission and 
outcome assessment tools are detailed with 
explanation and background in the 
Introduction. I intend to give only a brief 
recapitulation which assessment measures 
were used in the different papers.  
A. Paper I (CRP) 
We used WFNS, Fisher scale as admission 
assessment, CVS, infection status during the 
observation and outcome measures after one-
year with GOSE, NIHSS and Barthel score. 
GOSE was dichotomised in prognostic 
statistical calculations to poor (GOSE 1-4)  
Table 10.  The demographics, clinical and outcome 
parameters of 41 patients in Paper IV. (CVS-cerebral 
vasospasm, Op/Embol- therapy modality, outcome 
parameters (GOSE, NIHSS, Barthel and how we 
dichotomised the scales) 
 
and favourable (GOSE 5-8), NIHSS, as no 
focal deficit detected (NIHSS=0,) and patient 
with focal deficit (NIHSS>0). Finally the 
Barthel Index was dichotomised as no help 
required during daily ADL (Barthel=100) 
and assistance nedded (Barthel<100). 
B. Paper II (APOE) 
We utilised Hunt and Hess scale as 
admission neurological assessment, CVS was 
measured and followed and one-year 
Hunt & Hess All patients Sex Age CVS Op/Embol 
categories No. (%) Male/Female  (Mean, Min, Max, SD) Spasm / No spasm Surgical / Radiol. 
H&H 1 8 (19.5%) 5 / 3 51.3 (37, 66, 12.5) 3 / 5 1 / 7 
H&H 2 9 (22.0%) 0 / 9 48.2 (20, 81, 21.7) 4 / 5 1 / 8 
H&H 3 9 (22.0%) 2 / 7 56.0 (42, 65, 8.5) 5 / 4 1 / 8 
H&H 4 10 (24.4%) 0 / 10 60.0 (40, 75, 8.9) 4 / 6 1 / 9 
H&H 5 5 (12.2%) 1 / 4 54.2 (39, 69, 10.8) 4 / 1 0 / 5 
Total 41 (100%) 8 / 33 54.2 (20, 81, 13.5) 20 / 21 4 / 37 
χ2(p-value) - 0.007 0.575 0.575 0.958 
GOSE 
 
Outcome  NIHSS 
 
Barthel 
 
GOSE 1 7 (17.1%)  NIHSS 0 p     23 (56.1%) Dead  7 (17.1%) 
GOSE 2 0 (0.0%)  NIHSS 1-10 p  7 (17.1%) 0-9  p 4 (9.8%) 
GOSE 3 6 (14.6%)  NIHSS 11-20 p 2 (4.9%) 10-39 p 1 (2.4%) 
GOSE 4 0 (0.0%) Poor         13(31.7%) NIHSS 21-42 p 2 (4.9%) 40-99 p 2 (4.9%) 
GOSE 5 8 (19.5%)  Dead 7 (17.1%) 100  p 27 (65.9%) 
GOSE 6 8 (19.5%)   
GOSE 7 5 (12.2%)      
GOSE 8 7 (17.1%) Favorable 28(68.3%) For categorical variables n (%) is presented. 
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RESULTS  
I. Biochemical 
neuromarkers (BNMs) 
A. Neuron cell-injury markers: 
The BNMs below comprise an admixture of 
proteins recognized to be found in the 
central nervous system. They have been 
shown to have variable functions like 
structural-, transport-, receptor- and special 
purpose proteins within inflammation and 
coagulation. The common attribute of these 
proteins is that all of their concentrations in 
body fluids have been found to increase 
after neuronal injury. We have investigated 
nine BNMs in a pilot study in 41 patients 
after aSAH in Paper IV. The correlation 
calculations between the investigated BNMs 
and admission neurology, CVS and outcome 
measurements (GOSE, NIHSS, Barthel) are 
described in Table 12. 
Neuron Specific Enolase 
(NSE)  
NSE followed an irregular pattern, but a 
continuous rise from Day 0 (mean 2.82 
ng/ml, SD 2.78) to Day 12-14 (8.57 ng/ml, 
SD 7.38) could be observed. The maximum 
or mean values showed, however no 
correlation with H&H, vasospasm or the 
Tabell 12 Correlation table for neuropanel markers; max and mean values vs. Hunt &Hess scale, CVS, 
GOSE, NIHSS and Barthel index. Spearman’s rho coefficients and p-values are presented. Statistically 
significant values are highlighted and marked in grey. 8 
 
haplotype-based association analysis in 
unrelated individuals. This program is based 
on the maximum likelihood model and 
estimates ORs for each haplotype in relation 
to a reference haplotype (Tregouet and 
Garelle, 2007). 
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B. Glia cell-marker 
Glial Fibrillary Acidic 
Protein (GFAP) 
This glia cell-injury marker has been 
investigated in a previous study in partially 
overlapping aSAB patient material (Nylen et 
al. 2007). In our 41-patient material with the 
new biochip-array technique, we could not 
find an association between either the 
maximum or mean values of GFAP and the 
initial neurology (H&H), cerebral 
vasospasm (CVS) or any of the outcome 
parameters tested. (Spearman’s Rho was at 
best Rho= − 0.19, p=0.22). However, when 
plotting the results, there was a tendency of 
the poor outcome patients having higher 
initial values (Fig.15).  
 
C. Coagulation protein 
D-dimer (DDMR) 
DDMR is a fibrin degradation protein which 
is a product of fibrinolysis, a natural process 
of the organism dissolving a thrombus or a 
clot. As SAH entails a clot-formation, it has 
been proposed that the level of DDMR 
corresponds to the amount of blood 
exsanguinated from the aneurysm and 
consequently to the risk of vasospasm and 
outcome (Fujii et al. 1997). As DDMR is 
included in the neuropanel biochip of 
Randox UK, we 
aimed to test this 
coagulation 
protein, relatively 
new to SAB 
diagnostics.  
We found 
initially medium 
high values 
(mean: 376 
ng/ml, SD: 503) 
which decreased 
gradually, 
reaching its nadir 
on day 2 (180 ng/ml, SD: 134), thereafter 
increasing again to even higher levels and 
staying high during the whole observation 
period (day 12-14: mean 477 ng/ml, SD: 
372). Although, there is no difference in the 
initial course and levels of DDMR between 
the favourable and unfavourable group, the 
Figure 15 The course of GFAP in patients with poor and favourable outcome (dichotomous GOSE). 
Mean values and standard error of the mean (SEM) are presented 
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outcome parameters (GOSE, NIHSS, 
Barthel).  
Brain-Derived Neutrophic 
Factor (BDNF) 
BDNF did not follow any specific pattern 
during the observation period in our patient 
group. The mean values stayed around 1000 
pg/ml with daily variations ± 100 pg/ml. 
Consequently, no correlation could be 
discovered with any of the study parameters.  
Fatty Acid Binding 
Protein (FABP) 
FABP, a group of lipid-transport proteins, 
first derived from central and peripheral 
nervous system tissues, were also included 
in our investigation. It appeared to be a fast 
reacting marker with the highest values on 
day 0 (mean 6.67 ng/ml, SD 5.01) and 
continuously falling to day 3 (2.69 ng/ml, 
SD 2.18), thereafter increasing again, 
reaching a second peak on day 8 (4.56 
ng/ml, SD 7.45).  FABP correlated strongly, 
in contrast with the above markers, to all 
study parameters. (Spearman’s Rho 0.39-
0.57), p=0.022-<0.0001). The univariable 
ORs ranged between 1.43-2.19 and p values 
0.025-0.004. FABP had the best predictive 
qualities for CVS with ROCAUC=0.80 of all 
the measured BNMs. Besides, FABP proved 
to be a good predictor even for the outcome 
parameters (GOSE: ROCAUC=0.85, p=0.019; 
NIHSS: ROCAUC=0.83, p=0.004; Barthel: 
ROCAUC=0.83, p=0.025). Figures 14, 15, 16, 
17, 18, & 19 present the temporal course of 
those BNMs mentioned above and their 
mean values are depicted with standard error 
of the mean (SEM) split between the 
dichotomous groups of the parameters 
investigated. The unfavourable group, 
painted grey, represent the number of 
patients with CVS, n=20 (48.8%), poor 
outcome with dichotomised GOSE, n=13 
(31.7%), neurological deficit with NIHSS, 
n=18 (43.9%) and finally number of patients 
in need of help with ADL, Barthel n=14 
(34.1%). All tests were performed with 
univariable logistic regression. P-values, 
ORs and Area under ROC curves (ROCAUC) 
are based on original values not on the 
stratified groups. OR is the ratio for the odds 
for an increase of the predictor with one 
unit.  
  
OR (95%CI): 
Area under ROC curve (95%CI): 
p: 
1.43 (1.05-1.95) 
0.83 (0.70-0.96) 
0.0252 
OR (95%CI): 
Area under ROC curve (95%CI): 
p: 
2.19 (1.28-3.73) 
0.83 (0.69-0.96) 
0.0040 
OR (95%CI): 
Area under ROC curve (95%CI): 
p: 
OR (95%CI): 
Area under ROC curve (95%CI): 
p: 
1.47 (1.06-2.04) 
0.85 (0.72-0.98) 
0.0195 
2.05 (1.23-3.43) 
0.80 (0.66-0.94) 
0.0062 
Figure 14 . The course of Fatty Acid Binding Protein (FABP) 
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Barthel. The predictive qualities were all
significant, ranging between ROCAUC=0.69-
0.75. (Fig. 17) 
Tumour Necrosis Factor
Receptor 1. (TNFR1)
TNFR1 is one of the receptors of TNF-α,
which is recognised to act as mediator in
inflammatory processes. The soluble
TNFR1 and 2 are activated by TNF-α and 
having a longer half-life than the actual
cytokine, thereby acting as a more reliable 
measure of inflammation activity than its
ligand. TNFR1 demonstrated a continuously
rising pattern. The correlation between the
early diagnostic scales are weak (H&H – 
non significant, CVS – Rho=0.32, p=0.040), 
but becomes strong (Rho>0.5, p<0.01) with 
the outcome measures. It has the best
predictive strength of all the BNMs 
investigated for poor – good outcome with 
ROCAUC=0.87, p=0.0028, bordering the
conclusion: excellent predictor according to
Swets (Swets 1988). (Fig.18)
Interleukin-6 (IL-6)
IL6 is one of the most important pro-
inflammatory cytokines and mediator of
fever through prostaglandin (especially
PGE2) production. As found in smooth 
muscle cells in blood vessel walls it is 
involved in vessel regulation during 
inflammation. It has recently been assigned
new functions as neuropoietin for its
positive neural properties (Vezzani and
Viviani 2015). Not surprisingly, IL6 is
interesting as a marker of inflammation and 
regeneration after SAB. As nearly all
cytokines are fast reacting mediators, IL-6 
demonstrated rapid rise after the insult, 
reaching its peak on day2-4. The correlation
was good on all the observation parameters
(Rho=0.36-0.51, p=0.019-0.0006), but due
to its fast reaction and with regard of its
OR (95%CI):
Area under ROC curve (95%CI):
765.8 (8.50-
69038)
0 84 (0 71 0 96)
OR (95%CI):
Area under ROC curve (95%CI):
287.8 (4.18-
19812)
0 76 (0 60 0 91)
OR (95%CI):
Area under ROC curve (95%CI):
1514.8 (12.46-
184188)
0 87 (0 75 0 98)
OR (95%CI):
Area under ROC curve (95%CI):
21.08(0.95-
469.0)
 ( )
Figure 18. TNFR1’s course with CVS and outcome measures
OR (95%CI):
Area under ROC curve 
(95%CI):
1.03 (0.99-
1.08)
0 76 (0 60
OR (95%CI):
Area under ROC curve 
(95%CI):
1.02 (0.98-
1.05)
0 65 (0 48
OR (95%CI):
Area under ROC curve 
(95%CI):
1.03 (0.99-
1.07)
0 75 (0 59
OR (95%CI):
Area under ROC curve 
(95%CI):
1.09 (1.02-
1.16)
0 80 (0 65
Figure 19. The development of Interleukin-6 (IL6) during the first two weeks in patients with or without vasospasm
and favourable/unfavourable dichotomous groups of outcome scales
4 
gap becomes noticeable in the late course 
(after day4) between these cohorts. The 
correlation is nevertheless significant 
between the course of DDMR and H&H 
(Rho=0.77, p<0.001), CVS (Rho =0.31, 
p=0.046) and all of the outcome parameters. 
Even though mean values give significant 
correlations to all outcome measures, 
interestingly the maximum values give 25-
30% higher correlation coefficients, hence 
considerably lower p values. This 
characteristic is unique among BMNs. 
Because of the similar patterns between 
patients with poor and good outcome up 
until day3-4, the DDMRs predictive value 
reaches significance only to calculate focal 
deficit (NIHSS; ROCAUC= 0.71, p=0.041). 
(Fig.16) 
D. Inflammation markers 
Probably the most prominent reaction 
occurring after the “early injury” of the 
initial haemorrhage is inflammation. It is the 
tissue’s reaction to foreign substances, and 
part of the immunological processes of 
healing. It is one of the most studied 
pathological systems and hundreds of 
mediators, substances, ligands and receptors 
are described to be involved in this process. 
Randox, UK-s immunological biochip-
plate has chosen four of them to be included 
in their diagnostic neuro-panel. 
Neutrophil Gelatinase-
Associated Lipocalin 
(NGAL) 
NGAL, or Lipocalin-2 has only been 
previously investigated in one study in 
patients with aSAH (Serra et al. 2014). 
NGAL showed a weak, nevertheless 
significant correlation to CVS (Rho=0.33, 
p=0.032), NIHSS (Rho=0.38, p=0.014) and 
Barthel (Rho=-0.32, p=0.040). The temporal 
course of the marker showed a clear 
difference between the worse/better patients 
in regard of CVS, GOSE, NIHSS, and 
OR (95%CI):
Area under ROC curve 
(95%CI):
1.00 (1.00-
1.01) 
0.75 (0.60-  
OR (95%CI):
Area under ROC curve 
(95%CI):
1.00 (1.00-
1.01) 
0.68 (0.51-  
OR (95%CI):
Area under ROC curve 
(95%CI):
1.00 (1.00-
1.01) 
0.74 (0.59-  
OR (95%CI):
Area under ROC curve 
(95%CI):
1.00 (1.00-
1.01) 
0.71 (0.54-  
Figure 16. The course of DDMR in patients in the dichotomous observation parameters (CVS, GOSE, NIHSS, 
Barthel)
Figure 17 The course of NGAL between the worse and better patients with regards of the scales measured 
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Figure 19. The development of Interleukin-6 (IL6) during the first two weeks in patients with or without vasospasm 
and favourable/unfavourable dichotomous groups of outcome scales 
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gap becomes noticeable in the late course 
(after day4) between these cohorts. The 
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(Rho=0.77, p<0.001), CVS (Rho =0.31, 
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Figure 16. The course of DDMR in patients in the dichotomous observation parameters (CVS, GOSE, NIHSS, 
Barthel) 
Figure 17 The course of NGAL between the worse and better patients with regards of the scales measured 
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endovascularly treated aneurysms were 
enrolled in this study. The patients’ 
demographics, neurological status at first 
examination, radiological grading, infectious 
status during observation and their CRP 
values during the first week of treatment are 
described in Table 1 in Paper I.  We could 
demonstrate a continuous rise of CRP values 
from normal at day 0 (median 5 mg/L, IQR 
5-7) to its peak at day 3-4, (median value 53 
mg/L, IQR 24-100). The values decreased 
after this peak until day 8 without 
normalising. (median 24 mg/L, IQR 10-47). 
The changes between each subsequent day 
were significant, apart from the peak. The 
course of CRP levels in the first 8 days is 
depicted in Fig.21.  
This change was independent from the status 
of infection. We were the first to describe 
this temporal course (Csajbok et al. 2005) 
and were intrigued by the result, which 
corresponded with our clinical experience. 
We tested if there was a difference in the 
course of CRP development between the 
patients with unfavourable and favourable 
outcome. The same boxplot, split between 
these patient groups confirmed the result 
(Fig.22). 
The linear regression lines showed a 
stronger association between the mean CRP 
values in the first week and long-term 
outcome, measured by GOSE, compared to 
the radiological scale Fisher or initial 
neurology categorised by the World 
Federation of 
Neurological 
Surgeons Scale 
(WFNS) in this 
patient group. 
(Fig.23) The 
correlation 
coefficients 
(Spearman’s Rho) 
confirmed the 
stronger connection 
between CRPmean and 
CRPmax to GOSE (-
0.49, -0.45, 
p<0.0001) and 
NIHSS (0.45, 0.45, 
Figure 22 Box plot of CRP values from day 0 to day 8 with median, mean and IQR. 
Differences tested with Wilcoxon’s signed rank test 
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peak, it showed predictive quality only with 
CVS (ROCAUC=0.8, p=0.0097). (Fig.19) 
 
1. C - Reactive 
Protein (CRP) 
CRP measurement, as the most accepted and 
utilised inflammation marker, was included 
in the Randox UK-s stroke-diagnostic 
neuro-panel. As this biochip-controlled test 
was originally designed to diagnose 
ischemic stroke, it included the high-
sensitivity CRP 
(hsCRP) assay 
version with a 
dynamic range of 0-
15 mg/L. We found 
that hsCRP reached 
the upper limit soon 
after the bleeding in 
many cases, and 
stayed there 3-4 days. 
It decreased rapidly 
without normalising 
in the favourable 
patient-group and 
more slowly, 
remaining at a higher level in the 
unfavourable group. Although the values 
struck the ceiling of measurement in several 
cases, it showed nonetheless significant 
correlation to most of the clinical rating 
scales (H&H, CVS, GOSE, Barthel).  
CRP’s prospective value as a neuromarker 
(BNM) was explored comprehensively in 
Paper I and its potential as an outcome 
predictor was evaluated early in the course 
of aSAB. 98 consecutive patients with 
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Figure 20 HsCRP-s progress after aSAH plotted separately for favourable/unfavourable patient-groups 
Figure 21 Box plot of CRP values from day 0 to day 8 with median, mean and IQR. 
Differences tested with Wilcoxon’s signed rank test. 
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outcome. 
The area under the 
ROC curve 
(AUCROC) that can 
describe accuracy of 
the test (Swets 1988) 
showed moderate 
accuracy for CRPmean 
and CRPmax (0.76, 
p<0.001; 0.74, 
p<0.001), poor 
accuracy for WFNS 
(0.67, p=0.008) and 
no predictive value 
for Fisher scale (0.57, p=0.14), rendering 
WFNS and Fisher scale inapplicable for 
outcome prediction. In our endeavour to find 
even earlier prognostics, we added CRP 
values on day 2 and 3 to our ROC analysis 
and found surprisingly, that already CRPday2 
provided better prognostic accuracy 
(AUCROC =0.7, p=0.002) than WFNS and 
Fisher scale.  
The logistic 
regression 
analysis could 
offer us a 
probability curve 
to predict poor 
outcome for the 
best predictors in 
relation to the 
CRP values 
(Fig.25). This is 
the first time a 
practical 
Figure 24 ROC curve of CRPmean, CRPmax, CRP∆, WFNS score and Fisher scale for 
prediction of outcome 
 Fugure 25 Probability of poor outcome expressed as a measurement of CRP on day 2 
and day 3, CRPmean and CRPmax during the first week after aSAH calculated from the 
logistic regression model 
8 
 
p<0.0001) compared to Fisher scale   (-0.25, 
p=0.01; 0.16, p=0.16) and WFNS (-0.44, 
p<0.0001; 0.27, p=0.001).  
As CRP’s correlation to outcome was 
comparable or better than initial clinical 
status or radiological evaluation, we tested 
its predictive qualities in a univariable 
logistic regression model. In Table 13, the 
univariable odds ratios (OR) were presented 
with p-values. The receiver operator curve 
(ROC) was drawn to estimate the 
parameters’ predictive strength and choosing 
a cut-off point. (Fig. 24)  
In a multivariable logistic model, after 
adjustment for age, sex, WFNS and Fisher 
scale, the CRP values were the only variable 
which remained significant in relationship to 
Figure 23  GOSE – CRPmean, GOSE – WFNS score and GOSE-Fisher scatter plot with linear regression line 
and 95% confidence interval of the mean  
Table 13 Univariable logistic regression analysis - prediction of poor outcome 
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B. Chromosome 9p21  
As we did not find an association between 
subarachnoid haemorrhage’s 
pathophysiology and the well-known, 
previously described potential susceptibility 
gene on chromosome 19q13.2, we turned to 
the Department of Genetics at the 
Sahlgrenska University Hospital to identify 
other possible genetic markers.  
In Paper III, we described a genetic study 
where variants of a gene in a particular 
chromosome-segment were investigated. We 
examined whether an association could be 
identified between single nucleotide 
polymorphisms (SNPs) and subarachnoid 
haemorrhage by 
comparing the 
patients’ and 
controls’ genetic 
configuration at those 
particular base-pairs.  
With genome wide 
association studies 
(GWAS) in European 
and Japanese 
populations 
chromosome 9p21 
was linked to 
intracranial 
aneurysms (IA) 
(Bilguvar et al. 2008). 
A 44 kbp (kilo base-
pair) long DNA sequence was searched with 
the help of the HapMap database and the 
HaploView program. This exercise resulted 
in six tagged SNPs (Fig.27). 
The genotype frequencies at those base-pars 
were analysed both in patients and controls 
and the uncommon allele determined. One 
SNP, rs10757278 emerged already at this 
stage as the only SNP showing significant 
difference between controls and patients. 
(p=0.02) The uncommon alleles were 
subsequently inserted in a univariable 
regression analysis and ORs were 
calculated. Two of the alleles showed 
significant ORs to develop aSAH.  
 Figure 26 Proportion of APOE ε4 and nonAPOE ε4 allele carriers in healthy 
controls and SAH patients, in SAH patients with CVS and in SAH patient with poor 
outcome after one year. 
(SAH – subarachnoid haemorrhage,  
CVS – cerebral vasospasm (Spasm),  
Poor outcome – Glasgow Outcome Scale Extended (GOSE) 1-4,  
Focal deficit - National Institute of Health Stroke Scale (NIHSS) = 0 
APOE ε4 – Apolipoprotein E gen, allele 4) 
10 
 
probability estimation has been provided 
based on early CRP values. 
II. Genetic 
neuromarkers (GNM) 
A. ApolipoproteinΕ  gene 
(APOε) 
The APOE ε2/ε3/ε4 polymorphism is 
probably is probably the most investigated 
genetic allele variation in connection with 
neurological diseases and pathophysiology. 
As described in the introduction two single 
nucleotide polypeptides (SNPs) rs7412 and 
rs429358 on chromosome 19 are associated 
with three different allele variants: ε2, ε3 
and ε4. As APOEε3 is the wild type, and 
most common allele and ε4 is the variant 
with the strongest association with 
neurodegeneration (Alzheimer’s disease in 
particular), we have studied the effect of 
APOEε4 on the incidence, course, 
complications and outcome of aSAH in 
West-Swedish population and patient 
cohorts in Paper II. As described in Table 1 
of Paper II, we had 148 patients, with aSAH 
and compared APOE genotype frequencies 
in this group to those in a control group 
consisting of 221 healthy individuals. 
The result was surprisingly unambiguous 
despite previous studies’ contradictory 
conclusions.  The controls and patients were 
matching in all aspects (gender, 
geographical area) apart from age (patients 
mean=55.3 years, controls mean=72.3, 
p=<0.001). The different cohorts’ Apoε 
constellation showed, however virtually the 
same ε4 proportions. (p=0.96) As in other 
studies (Linn et al. 1996), gender proved to 
be a risk factor for aSAH, as 73% of the 
patients were female (108), compared to 
27% male (40), resulting in a univariable 
OR of 1.86 (1.19-2.92, p<0.001). No 
differences in allelic frequencies were noted 
between the sexes in controls (p=0.15) and 
patient (p=0.79). (Fig.26)  
Among the therapy alternatives (surgical, 
endovascular and conservative), no 
difference was registered according to the 
patients’ ε4 carrier status. (p=0.68) 
As one can clearly note from Fig.16, neither 
in vasospasm (CVS) nor in long-term 
outcome measures, assessed with GOSE, 
NIHSS, and Barthel score, the APOEε4 
carrier frequencies differed significantly. 
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DISCUSSION 
 
I. General 
considerations 
In our studies, we have focused on a patient -
group with aneurysmal subarachnoid 
haemorrhage. We have explored different 
biochemical and genetic markers’ relation to 
the incidence of the bleeding, the course 
during the disease development, the 
complication frequency and the different 
measures of outcome (Papers I-III). In the 
final study, we evaluated the usefulness of an 
innovative biochip-array for monitoring and 
prediction of outcome in this patient cohort 
(Paper IV). Our main findings were the 
associations or the absence of associatiations, 
between these neuromarkers and one or more 
aspects of this devastating haemorrhagic 
stroke entity. Some of the links we have 
discovered were strong enough to enable us 
to make predictions about general outcome. 
Our overall aim was to look at these results 
from an intensive care physician’s point of 
view but with a neurologist’s sense for 
details and a neurosurgeon’s focus on the 
whole picture. Our tools, to achieve this were 
a prospective cohort patient population with 
a complete inclusion, to gather so many 
patients as possible, daily or almost daily 
serum sampling, noting all details of the 
condition and treatment of the patients and 
finally a meticulous long-term follow-up.  
We lost a mere 0.6 % (12) of the identified, 
eligible patients from inclusion during the 
two-year study period, which stretched over 
three years from inclusion to final outcome 
assessment. The study borders feasibility for 
a single-centre in this respect. Retrospective, 
multi-centre or meta-analysis studies are the 
next step to increase the number of 
participants with other types of 
methodological problems to consider. We 
had a general unfavourable outcome, i.e. 
death or dependency of 32% among the 
aSAH patients which is in line with other 
large studies (the ISAT study) (Molyneux et 
al., 2002; Rosen and Macdonald, 2004) and 
even the proportion of poor grade 
subarachnoid haemorrhage was 
corresponding with 22% as in Rosen’s study 
with 3567 participants. This indicates that 
our study-population has similar distribution 
as larger studies in the world, which makes 
our conclusions generally applicable for 
other subarachnoid patient groups in similar 
hospital environment. 
These studies were not designed to compare 
therapy alternatives. The figures were merely 
described as methodological information for 
parallel interpretation with other studies in 
the literature. The majority, 71% of our 
patients were endovascularly treated; surgical 
12 
 
As smoking and hypertension were 
identified as main modifying factors, 
we determined if the SNPs showing 
association with aSAH were 
independent from these recognised 
risk elements. Multivariable 
regression model showed 
significance solely for the same 
SNP, rs10757278 G allele, as an 
independent marker. It showed even 
additive effect for homozygous GG 
subjects with univariable ORs of 
1.38 (1.18-163) and 1.72 (1.39-2.13) 
for heterozygous and homozygous 
individuals respectively.  
  
 Figure 27 Graphic representation of the linkage disequilibrium 
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DISCUSSION 
 
I. General 
considerations 
In our studies, we have focused on a patient -
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biochemical and genetic markers’ relation to 
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our conclusions generally applicable for 
other subarachnoid patient groups in similar 
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patients were endovascularly treated; surgical 
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Seizures present an extremely complicating 
dimension to initial assessment.  Nearly one 
in ten patients was found having early-onset 
seizures (EOS) at admission (Fung et al., 
2015), of whom 66% were graded poor on 
clinical scales. 68% of these patients 
achieved nevertheless good outcome at 6 
month. Furthermore, patients having seizures 
are treated on site with anti-epileptics (often 
benzodiazepines) which affect the level of 
consciousness, resulting in worse clinical 
scores than the bleeding would have 
warranted. This fact adds to the explanation 
why initial neurology fails to predict 
outcome reliably. (Paper I) These seizures 
may even proceed to non-convulsive seizures 
(NCSs) that have been implicated in the 
aetiology of secondary brain injury. Claassen 
and co-workers observed 479 SAH patients 
and found 11% having NCSs and could 
directly associate their condition to 
inflammatory state with markers like TNFR1 
and hs-CRP. (Claassen et al., 2014)  
The clinical appearance of aSAH is highly 
altered by the patients’ co-morbidity status. 
Severe congestive heart failure, COPD, pre-
existing neurological disease and psychiatric 
conditions may complicate the initial 
assessment and definitely affect long-term 
outcome to the worse. It led to development 
of Charlson Co-morbidity Index (CCI) and 
its application on aSAH patients. (Boogaarts 
et al., 2014) If this index had been available 
at the time of study design, it would have 
been easier to adjust the outcome for co-
morbidity.  
Finally two facts need to be mentioned, 
which might have confounded some aspects 
of the results. A difference might have 
emerged between patients presenting directly 
at the University Hospital compared to those, 
being referred from other health facilities 
with the ambulance services. In the letter 
case we were compelled to seek secondary 
information on patients’ initial status by 
consulting local hospital journals and 
ambulance records. These patients came 
frequently sedated, sometimes anaesthetised 
and in respirator as recommended by inter-
hospital transport protocol based on current 
knowledge (Uren et al., 2009). Neurological 
investigations were seriously influenced, 
often impeded on these patients.  
Technical circumstances compelled us to 
exclude 12 patients, 3 of whom were foreign 
citizens, presumably not available for 
outcome investigations and in 9 cases, 
informed consents could not be obtained or 
were withdrawn. These cases might have 
affected outcome, as the main reason for 
failure to obtain consent was that these 
patients were severely affected by their 
illness and could not sign it themselves and 
relatives could not be traced.  It might have 
been however compensated by those few, 
who withdrew their consent because they 
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clipping was therapy alternative in 26% and 
3% were treated conservatively i.e. basic 
intensive care. These figures vary both 
geographically and in time in the literature. 
In a Chinese centre all good-grade aSAH 
patients (H&H 1-2) were operated in 2003, 
the rest were conservatively treated (Tang et 
al., 2003), while in a Scottish centre 11% of 
the patients operated and 89 treated with 
coiling (Teo et al., 2015). At the same 
department, the therapy trend changed in 
favour of coiling from 11% in 1995 to 89% 
in 2003 and has continued on that level since 
then. This paradigm shift happened after the 
ISAT study, although the difference in RR 
(relative risk) reduction between the 
endovascular vs. neurosurgical treatment 
groups was only 15% with 2-3% higher risk 
of re-bleeding in the coiling group. The 18-
year follow-up of this material has been 
published this year (Molyneux et al., 2015)  
and it showed that the difference in 
dependency is not significant, but the chance 
for being alive 10 years after treatment is 
higher in the coil-group (OR: 1.34), however 
with 1,7% re-bleeding risk from the target 
aneurysm.  
II. Patient 
considerations 
There is one weakness in all third-level 
referral hospital driven clinical trials; they all 
have flawed inclusion, however thoroughly 
they try to avoid it. There is an important 
group of patients in poor condition, who 
never reach these university hospitals, 
thereby the public impact of the diseases is 
much larger than the actual figures and the 
outcome is worse than claimed (Nylen, 
2007). Unfortunately it is only disease 
demographic studies, based on records and 
data-bases which can put these figures right.  
The positive fact is that different data exist to 
assess the initial status of SAH patients and 
the severity of the haemorrhage: clinical-, 
radiological-, laboratory examination, lumbar 
puncture and not the least the experience of 
the clinician. They complement one-another 
and finally they form a basis for decision 
with quite high sensitivity and specificity. To 
have the ambition that one sole modality, let 
alone a single marker would substitute this 
complex decision-making system is over-
pretentious.  
One of the more challenging facts is the 
diversity of clinical picture the subarachnoid 
haemorrhage patients present. There is a 
large dispersion in the time-frame they 
appear in the emergency department, from a 
few minutes to a couple of days or even 
weeks. There were some patients, presenting 
late on the medical or neurological wards 
with mild symptoms, which later could be 
related to aSAH. Most of these patients were 
unfortunately ineligible for our studies, 
elapsing more than 2 days from the bleeding.  
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Before performing patient selection for study 
resulting in Paper I (CRP), we had some 
methodological discussions how we should 
relate to indwelling ventricular catheter or 
parenchymal pressure transducer insertion as 
a confounding factor in CRP elevation. We 
came to the conclusion that we confirm the 
fact that catheter-insertion procedures initiate 
an inflammatory reaction (Alhadad et al., 
2007; Almagor et al., 2003) but not in the 
magnitude as in major operations inclusive 
craniotomy for cortical tumour operations 
(Mirzayan et al., 2007). Although there is no 
literature support, it is plausible, that skull-
base surgery as clipping an aneurysm results 
in an even larger inflammatory process than 
craniotomy for cortical tumours, thereby 
constituting an even more important 
confounder for CRP elevation. This fact is 
the most important criticism for previous 
CRP studies in SAH patients. Ventricular 
catheter or parenchymal pressure transducer 
were placed in patients, either in need of 
invasive intracranial pressure monitoring, 
CSF drainage, or both because of a SAH 
complication (hydrocephalus, DCI, CI). We 
decided that exclusion of patients with 
indwelling ventricular or parenchymal 
catheter (42% of study I. population) would 
result in a skewed inclusion of aSAH patients 
(only the very best of patients and the 
moribund ones) and that the results could no 
longer be applied for this patient group.  
In Paper III, performing qPCR (quantitative 
real-time polymerase chain reaction) assay 
for rs1333040 SNP, the test failed and due to 
probe C_8766795_10 failure it could not be 
repeated. This SNP which is part of the 
cyclin-dependent kinase inhibitor 2 B-
antisense RNA1 (CDKN2B-AS1) a non-
coding RNA sequence, better known as 
ANRIL (antisense non-coding RNA in the 
INK4 locus), which has a function of 
silencing other genes in the proximity. 
(Popov and Gil, 2010). It is rather 
unfortunate that this particular assay failed as 
it was associated with atherosclerosis, 
cardiovascular diseases, diabetes type 2, and 
most of all intracranial aneurysms. (Abrantes 
et al., 2015; Alg et al., 2013).  
Our follow-up, as I described in the 
introduction, is our pride, but one may argue 
that even longer monitoring would have been 
desirable (Molyneux et al., 2015). Wilson 
and co-workers showed, however, that in the 
time-course of recovery, following poor-
grade aneurysm in 88 patients, the largest 
improvement occurred between hospital 
discharge and 6 month (23.5%, which proved 
to be significant). Further recovery measured 
by modified Rankin scale, was 18% between 
6 months and 1 year and further 19% 
between 1 year and 3 years. They did not 
differ significantly between each-other 
(Wilson et al., 2013). Nylén pointed out the 
risks associated with extended follow-ups, 
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were simply not interested in further blood 
samples, neurological investigations or/and 
an impending LP in an adjoining study.  
III. Methodological 
considerations 
When we designed these studies no data 
existed on many of the neuromarkers’ kinetic 
properties. Some of them are fast markers 
(FABP, TNFR1, DDMR) increasing within 
hours, some even within minutes, others take 
days to rise (CRP). Even circadian rhythm is 
described in some of the markers (FABP) 
(Pelsers et al., 1999). The admission 
sampling, which could fall on day0, day1 or 
day2 could be taken at any hour of the day, 
the following samples were taken 
meticulously the same hour every day.  This 
fact could indicate a wider technical 
dispersion of the data on the initial days.  
As in all patient related clinical studies, we 
also have data samples missing. In our case, 
the blood-sample collection’s adherence to 
study protocol was around 87%, depending 
on the patient selection for the study, 
meaning that 13% of the blood values never 
reached the study register (not taken, sample 
foul, laboratory error). This led to the 
exclusion of 13 patients from Paper I due to 
difficulty in calculating the area under curve 
(AUC) in serial data. After publication, we 
have solved this problem, by using weighted 
(geometric) mean values for the time -series.  
After recalculating the figures for the whole 
sample, it led to the same conclusion, only 
changing the results by the second decimal.  
These studies were not aimed to parallel 
treatment strategies (surgical clipping vs. 
endovascular coiling) and these data were 
presented of pure descriptive reasons only, so 
it can be viewed in relation to other studies in 
the literature.  However, out-of-study 
comparison showed similar results as 
published in much larger multicentre 
investigations, e.g. the ISAT or BRAT study. 
(Molyneux et al., 2002; Spetzler et al., 2015) 
For the sake of interest, data taken from 
Paper II show 28% and 30% dead or 
dependency, 46% and 41% detectable 
neurological deficit and 28% and 33% ADL 
assistance necessity for operated and coiled 
patients respectively at one-year follow up. 
None of the figures showed statistically 
secured difference, only a slight tendency to 
more focal deficit after surgery and slightly 
more assistance requirement after coiling. 
One could argue that the more severe the 
SAH (volume effect, intra-parenchymal 
component, herniation risk), the larger is the 
possibility for neurosurgical intervention 
(clipping), thus it would skew the outcome. 
However, this point is usually counteracted 
by the fact that the most elderly and patients 
with most severe co-morbidity tended to be 
treated endovascularly (coiling). 
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based on a five-criterion system, awarding 0 
or 1 point. The criteria were age (<50, >50 
years), H&H (no coma I-III, coma IV-V), 
Fisher scale (1-2, 3-4), aneurysm size (<10, 
>10 mm), giant posterior circulation lesion 
(no, yes). Scores are from 0-5 (Ogilvy and 
Carter, 1998). 
In his modified MGH-score (m-MGH), 
Lagares changed the level of consciousness 
to dichotomised WFNS scale (I, II-III, IV-V), 
otherwise similar to above and claimed to 
have better performance (Lagares et al., 
2005). 
GCS grading system (GCS-GS) is 
compressed version of the GCS system, there 
GCS points is put into a 5-scale system. (15, 
14-12, 11-9, 8-6, 5-3). It preformed 
reportedly as well as WFNS and GCS.  
NIS-SSS, Nationwide Inpatient Sample 
(American ICD-9 based administrative 
database) SAH Severity Score is developed 
for database demographic studies to control 
for SAH severity. Patient selection with the 
diagnosis codes for coma, stupor, 
hydrocephalus, paresis/plegia, aphasia and 
cranial-nerve defect as well as treatment 
codes for ventriculostomi, CSF shunt and 
mechanical ventilation were collected and 
univariate logistic regression coefficient 
calculated. NIS-SSS was derived from a 
weighted sum of these coefficients. It was 
validated in more than 100,000 patients and 
then performance tested. It performed better 
than H&H for outcome prediction 
(Washington et al., 2014). 
The FOUR score, full outline of 
unresponsiveness score was developed after 
realising the shortcomings of the GCS 
system on brainstem reflexes. It gives 0-4 
points in four functions; eye movement, 
motor response, brainstem reflexes (pupil, 
cornea, cough), and respiration. According to 
records, it performs similar to GCS (Chen et 
al., 2013). 
The HAIR score is a prediction model 
comprising of 4 attributes of SAH. It gives 
different points in different severity on a non-
linear scale. H&H (I-III0, IV1, V4), 
Age (<600, 60-801, >802), Intra-
ventricular haemorrhage (IVH) (no0, 
yes1) and Re-bleeding (no0, yes1). 
Scores 0 –7 predict in-hospital mortality 
between 0.9 – 83% evenly distributed (Lee et 
al., 2014). 
Takagi et al. had an entirely mathematical 
approach of the allocation of grading based 
on the GCS. He was using combinatorial 
methods to divide the 15 points into 5 
categories. The integrated differences led to 
the Grading Scale based on GCS (GSbGCS): 
I –15, II –14-11, III –10-8, IV –7-4, V –3. 
They claimed more symmetrical patient -
distribution and better prediction 
performance then WFNS and they promised 
an easy adjustment if therapy results 
improved (Takagi et al., 1999). 
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including increased number of drop-outs, 
changed social and financial status and other 
confounding circumstances which would 
cloud the disease-dependent outcome (Nylen, 
2007). On the other hand, one cannot deny 
the fact, that the 37% progress in 
neurological recovery between 6 month and 
3 years in the Wilson study, is a more 
substantial improvement than that of from 
discharge to 6 month (and statistically 
significant, if one after-calculates the 
figures). This is one of the reasons why very 
long-time (10-15 years) follow-up is under 
way in our aSAH patient -group. Another 
reason is to confirm a recent finding from 
Lindgren et al. that aSAH patients, even long 
time after their ictus, still die of 
cerebrovascular reasons, unlike the general 
population, where cardiovascular 
explanations are the most frequent causes of 
death (Lindgren et al., 2015). 
IV. Classification 
considerations 
The diagnostic and severity scales detailed in 
the introduction (RLS85, H&H, GCS, 
WFNS, Fisher scale) are still valid today, 
although many of them are modified and 
numerous new ones enrich the collection. I 
give a brief summary of the proposed 
changes and the potentially new scales to 
use. The reason for this passionate interest in 
modifying the old scales or inventing new 
ones lies in the fact that nearly all of them 
perform poorly in outcome predictions. 
There is an inherent conflict between 
designing and using a diagnostic scale. The 
easier, more user-friendly a scale is (less 
categories) the less mathematical chance it 
has for good outcome prediction. Conversely, 
the more detailed, more points / categories it 
has, the less popular it becomes but has the 
potential (at least mathematically) for better 
prediction. This ambiguity may contribute to 
the fact that new prediction models appear 
frequently in the literature, although none of 
them transferred to clinical practice (Jaja et 
al., 2013). 
A. Diagnostic scales 
One of the modifications to the WFNS (m-
WFNS) scale was suggested by Sano et al. 
by moving GCS 14 to WFNS II and GCS 13 
to WFNS III, regardless of focal deficit. It 
eliminates the assessment on double axis, 
which makes the scale easier to use (Sano et 
al., 2015). 
SAH score from Naval and co-workers 
proposed a summary point system from GCS 
(1-4 points), age (1– 4 points), medical 
comorbidities (1– 3 points), which resulted in 
9 categories and giving, according to the 
authors, superior prediction to WFNS 
(AUC=0.821 vs. 0.771). (Naval et al., 2014). 
MGH-score was developed in the 
Massachusetts General Hospital and was 
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some symptoms, 2 – slight disability (able 
not all, but the majority of activities), 3 – 
moderate disability (some help, able to 
walk), 4 – moderately severe disability 
(unable to walk or take care of body needs), 
5 – severe disability (bedridden, incontinent, 
constant nursing). The scale is often 
dichotomised to favourable outcome (mRS 0-
2) and dependent (mRs 3-5) (van Swieten et 
al., 1988). 
V. Remarks on genetic 
markers 
A. ApoE 
Apolipoprotein E is a major cholesterol 
transporter and an active regulator of 
lipoprotein metabolism in the body (Siest et 
al., 1995), and it is understandable that 
genetical variants coding different protein 
alternates have different effectivity in these 
mechanisms. Apart from role as a transporter 
in the periphery, it also assists neural 
transmission (Mauch et al., 2001) and in 
pathological conditions ApoE has been 
suggested to promote aggregation of amyloid 
β (Aβ) into plaques, which are characteristic 
of Alzheimer’s disease.   
The findings in our study in Paper III are 
fairly clear-cut. In our clinical material, we 
found no association of the variant allele 
APOEε4, either with the incidence of aSAH 
compared in a case control study or in an 
aSAH patient cohort study on CVS and long 
term-outcome. The results were so 
unambiguous, that if we 10-doubled the 
patient number in our material with the same 
dispersion of data, it would still lead to the 
same conclusion. As this question has been 
extensively researched even at this diagnostic 
entity, why is it still interesting?  
The answer lies on at least two levels. Firstly, 
the published studies demonstrate a 
surprisingly unequivocal conclusion, with 
approximately the same number presenting 
data for a negative effect of the altered allele 
on the outcome (Niskakangas et al., 2001; 
Tang et al., 2003; Leung et al., 2002) as 
demonstrating non-significant effect or no 
influence at all (Morris et al., 2004; 
Fontanella et al., 2007). One would think that 
meta-analysis could solve this discrepancy by 
collecting all data and calculating 
summarised-odds for this allele’s effect on 
several hundreds or thousands of patients. 
Unfortunately it is not always true, as those 
two recently published meta-analyses on this 
subject demonstrate (Lanterna et al., 2007; 
McColgan et al., 2010). They present equally 
conflicting conclusions, on the basis of, and 
it is similarly intriguing, only partially 
overlapping study-material. My 
interpretation of the current scientific opinion 
is that it is rather unclear on this matter, so I 
hope that I pushed the debate a little further.  
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The radiological assessment scales have 
evolved as well over the years. Claassen 
suggested a modification of the Fisher scale 
(mod Fisher scale) after showing the 
importance of bilateral intra-ventricular 
hematoma in the risk of DCI development. 
His suggestion was: 0 – no SAH, 1 – thin 
SAH, no IVH in both ventr., 2 – thin SAH, 
IVH in both ventr., 3 – thick SAH(>1mm), 
no IVH in both ventr., 4 – thick SAH, IVH in 
both ventr (Claassen et al., 2001). 
A new scale of radiological classification 
was proposed by Wilson, the Barrow 
Neurological Institute SAH scale (BNI-SAH 
Scale). It abandoned the importance of intra-
ventricular hematoma as a prognostic factor 
and concentrated entirely on the thickness of 
the SAH, measured perpendicular to the 
direction of cistern or fissure. The scale 
classified the SAH in 5 categories: 1 – No 
SAH, 2 – ≤ 5.0mm, 3 – >5-10 mm, 4 – > 10-
15 mm, 5 – >15 mm. The simplicity and 
Gauss distribution of patients in the scale are 
a huge advantage, but the scale needs 
validation in prospective studies (Wilson et 
al., 2012). 
It was finally relieving to read that the 
Charlson Comorbidity Index, where they 
allocate points by different coexisting 
diseases added no extra information in a 
SAH prognostic model (Boogaarts et al., 
2014). 
B. Outcome scales 
GOS, GOSE, NIHSS (although not strictly 
an outcome scale) and the Barthel Index, 
detailed in the Introduction, continue to serve 
as useful tools in outcome assessment. These 
scales can, and were in our research group 
(Nylen et al., 2007), supplemented by the 
Mini Mental State Examination (MMSE), 
which can subdivide the patients with 
favourable outcome by testing their higher 
cognitive functions. It requires speech or 
communication and is designed to test 
orientation, memory and attention (Folstein 
et al., 1975). 
NIS-SOM, as in Nationwide Inpatient 
Sample SAH Outcome Measure, as its sister 
NIS-SSS mentioned above is an 
administrative tool to control demographic 
and economic studies’ outcome and disease 
severity. It is derived from ICD-9 diagnose- 
and therapy codes and calculates regression 
coefficient-based measures of outcome. It is 
not for clinical use, but can be applied for 
hundreds of thousands of patients in 
databases (Washington et al., 2014). 
Finally, there is an outcome evaluation tool, 
which has gained wide acceptance in 
literature, and it might be the preferred 
assessment measure in the future; the 
modified Rankin scale (mRS). It reflects 
general disability in the sense of handicap 
rather than impairment. It is a six graded 
scale: 0 – no symptoms, 1 – no disability 
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Secondly, the frequency of genetic variation 
on APOE allele demonstrate a wide 
geographical dispersion on the whole planet 
(Gerdes, 2003) in Europe (Fontanella et al., 
2007) and especially in Northern-Europe 
(Lindekleiv et al., 2010; Juvela et al., 2009; 
Kern et al., 2015). The allele frequencies 
vary from the highest, 41% among pygmies 
in Africa to the lowest 5% in Sardinians. In 
Europe, there is clear South-North 
distribution from 5-6% in Sardinians and 
Greeks to 31% in the Lapps in the Northern 
regions of Scandinavia (Corbo and Scacchi, 
1999). This fact may influence how we 
interpret the results, found in another part of 
the world or even a neighbouring country and 
how we can apply this knowledge on our 
patients.  
One new aspect has emerged recently in the 
literature. Apart from the shear existence of 
an altered allele there might be other factors 
influencing its expression, transcription and 
action. Two Chinese studies looked at the 
polymorphism of promoter gen to APOE, as 
a probable factor influencing apoE protein 
expression and found that −219T allele, 
compared to −219G was negatively 
associated with both CVS and re-bleeding 
after aSAH (Wu et al., 2010; Yin et al., 
2015). 
B. 9p21 
The approximately 400 kbp large nucleotide 
sequence found on the short arm of the 9th 
chromosome in the human genome has been 
in the focus of genetic studies for three and a 
half decade and particularly genetic 
association studies, investigating vascular 
anomalies for the past 10 years. The intensity 
of research can be described with the hit 
result of 1831 articles published with the 
single search word: 9p21.  
In the investigated region we could identify 
six single nucleotide polymorphisms, SNPs, 
which had the potential to correlate to 
aneurysm rupture between an aSAH patient 
cohort and controls. We added an extra SNP, 
(rs1537378) which had been associated 
previously with ischemic stroke variant; large 
vessel disease (Gschwendtner et al., 2009). 
Unfortunately one SNP’s (rs133340) assay 
failed, as discussed above. One SNPs 
(rs10757278) distribution showed significant 
correlation between samples and controls. 
The univariable regression analysis showed 
significant ORs with two SNPs, but only the 
above mentioned SNP stayed significant, 
when we controlled the model for 
hypertension and smoking as further risk 
factors for aSAH.  
The identified SNP is included in a DNA 
code sequence, determining non-coding RNA 
structure in proximity of cyclin-dependent 
kinas inhibitor 2A and B (CDKN2A & B) 
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coding allele. It has been associated with 
most of all myocardial infarction (Fan et al., 
2013), but as the main function of this RNA 
sequence is to suppress other gene-
transcriptions, its attenuated function favours 
different tumour growth (Holdt et al., 2013). 
Subsequently many tumour types 
(melanoma, lymphatic leukaemia, 
oesophagus carcinoma, lung cancer, bladder 
cancer) have been associated with this 
anomaly (Lee et al., 2015).  
What is more interesting in an intracranial 
vessel-rupture point of view is that it is 
strongly associated with arterial stiffness 
(Phababpha et al., 2013), carotid artery 
stenosis (Bayoglu et al., 2014), intracranial 
arteriovenous vessel-malformation 
(Bendjilali et al., 2014) and through CARD8 
expression ANRIL increases stroke risk by 
promoting atherosclerosis (Bai et al., 2014; 
Kojima et al., 2014). 
The risk allele in the SNP is the G variant, 
the homozygote wild type, AA reduces risk 
to MI and intracranial aneurysm formation to 
OR: 0.77, heterozygote altered gene, AG 
increases risk to OR: 1.3 and homozygote, 
GG to OR: 1.6 (Helgadottir et al., 2008). A 
recent study from Japan explored the 
predisposing genes to aneurysm rupture 
(Nakaoka et al., 2014). They compared the 
gene expression profiles from 8 ruptured, 5 
unruptured IAs and 10 normal intracranial 
vessel-walls. They found 2 distinctive 
clusters in the ruptured IA group (early-late). 
In comparison with the normal cluster, they 
described 430 genes which were upregulated, 
mostly inflammatory, immuno-response an 
phagocytosis regulating genes (S100, 
calgranulin) and 617 genes which were 
down-regulated. Among these, they 
described ANRIL and Kruppel-like family of 
transcription factors which were interpreted 
as mechanical weakness in the vessel wall, as 
these genes had anti-inflammatory properties.   
If one thinks that our life is destined and our 
risk profile to diseases is genetically 
predetermined, one can find some 
consolation in Hindy’s study.  He 
investigated if an SNP, known to have close 
association to cardio-vascular diseases 
(CVD) in the 9p21 region, can be affected by 
environmental factors. He tested in a large 
cohort, whether wine and vegetable diet can 
influence the expression of rs4977574 allele 
and thereby alter disease incidence. He did 
find a reduction of ORs to CVD and an 
interaction of the SNP’s expression, 
modifying HDL cholesterol levels. 
VI.  Remarks on 
biochemical neuromarkers 
Biomarkers are qualitative and quantitative 
biological substances or characteristics, 
which define pathological conditions and 
may give indication on disease severity and 
type of therapy (Mouhieddine et al., 2015). I 
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2012; Jung et al., 2013). Furthermore, the 
study of Paper IV was not designed or 
powered to investigate any particular marker. 
It was rather a feasibility study to test a new 
array technique in a new patient population.  
B. CRP 
We have proved in Paper I that CRP 
increases after subarachnoid haemorrhage in 
endovascularly treated patients with a 
continuously rising pattern, independently 
from confounding factors. The course of 
CRP showed stronger correlation to outcome 
parameters than initial neurology or 
radiological evaluation. CRP’s reaction on 
SAH is not novel as it has been demonstrated 
since 2003 (Di Napoli and Papa, 2003) and 
repeated in different patient populations ever 
since (Feigin and Findlay, 2006; Rothoerl et 
al., 2006; Fountas et al., 2009; Jeon et al., 
2012; Juvela et al., 2012; Romero et al., 
2012; Hwang et al., 2013; Romero et al., 
2014; Badjatia et al., 2015). The unique 
aspect in our study is that we could eliminate 
one major confounding factor (craniotomy) 
and could ascertain a strong enough 
association between an early reaction of the 
marker and outcome to provide a prognostic 
curve. There are thousands of articles to 
prove that inflammatory processes are 
initiated immediately after the bleeding and 
most likely these reactions are more 
important to follow than neural damage 
mechanisms, as the inflammation always 
precedes neural injury and could potentially 
be reversed (Chalouhi et al., 2012). 
The initial theory was to correlate the course 
of CRP during the first 8 days (weighted 
mean) to outcome and it was a surprise, that 
not only the maximum value, but as early as 
on day 2, CRP could be used as independent 
predictor, with nearly the strength of the 
entire series. This finding could be clinically 
applicable, especially in unconscious, 
sedated patients who are not available for 
neurological examination. 
In Paper IV, we tested CRP again in a 
selection of patients as part of a validating 
process for a novel multi-array system. As 
the array was primarily designed for 
ischemic stroke detection, they employed 
high-sensitivity CRP, which proved to be too 
sensitive for the intense inflammatory 
reaction after SAH. As we described in Paper 
I, CRP increased to a median level of 53 
mg/ml, which exceeded the upper level of the 
hsCRP test in many samples. Despite this 
fact, it showed good prediction values in 
accordance with the results of Paper I. (Some 
samples however, may have appeared in both 
studies.) 
C. IL-6, TNFR1, NGAL  
All the inflammation markers on this 
neuropanel showed significant correlation to 
outcome parameters, CVS development and 
except TNFR1 even to admission neurology 
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endeavour to summarise below, if and how 
the substances we analysed fulfil the above 
criteria.   
A. BDNF, NSE, GFAP 
Neuromarkers above, closely described in the 
Introduction, have surprisingly not shown 
association with either CVS or any of the 
outcome parameters. There could be several 
reasons for the negative results, as all three 
markers have been described to increase in 
stroke (Siironen et al., 2007; Anand and 
Stead, 2005; Nylen et al., 2007) and after 
traumatic brain injury (Failla et al., 2015; 
Cheng et al., 2014; Nylen et al., 2006). 
We could see a negative association 
(although not significant) between BDNF 
and initial neurology, as is conceivable with 
a neurotrophic protein. It could be explained 
by the fact, that milder injury initiates 
neuronal reparation and apoptotic 
mechanisms, while a large haemorrhage 
instigates necrotic processes. BDNF is 
described to bind to specific Trkβ membrane 
receptors and the non-specific soluble p75 
receptors. Via both mechanisms it can 
activate NFκβ enzyme-system which leads to 
apoptosis.   
NSE is a promising biomarker, as it not only 
can reflect the extent of neuronal injury, but 
also persevere on a higher level mirroring a 
persisting secondary ischemia. (Cheng et al., 
2014) However there are several limitations 
in its use. NSE is affected profoundly by 
haemolysis, as erythrocytes contain a large 
amount of it. Furthermore, trauma patients, 
without head injury exhibited NSE increase 
not leading to neurological symptoms. 
Ischemia in abdominal organs in rodents has 
been documented to increase NSE (Pelinka et 
al., 2005). These facts have to be taken into 
consideration when interpreting NSE results, 
especially from TBI.  
It was rather dissatisfying to detect the lack 
of association to outcome in GFAP samples, 
as GFAP is one of the most encouraging 
neuro-injury markers with astrocyte/glia 
specificity. We encountered generally low 
levels in the whole sample, not unknown in 
literature (Mayer et al., 2013), nevertheless 
after scrutinising the data we found that the 
initial levels of GFAP showed a sharp rise, 
which normalised until day 3. The worse the 
patient’s initial neurology was, the higher the 
GFAP mean values reached underlining the 
fast-reacting character of this neuromarker. It 
even showed a secondary rise in moribund 
patients, corresponding to earlier findings in 
our group (Nylen et al., 2007). 
The reason we could not find an association 
with these markers may include the fact, that 
the disruption of the blood-brain barrier may 
have been different even within groups or 
that the markers leaked out to serum in an 
inconsistent pattern and/or inadequate 
concentration (Olivecrona and Koskinen, 
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Hypoxia induces a biochemical cascade, 
involving exitotoxicity, oxidative stress, 
leading to apoptosis. (Fig. 28) Initially the 
neutrophil leucocytes extravasate after 
engaging in rolling, activation and 
transmigration. They release freely soluble 
IL-6 receptors (sIL-6R), which attract their 
ligands produced by damaged cells, together 
with TNFα and its soluble receptor TNFR1 
and IL-1β (Probert et al., 2000).  These 
cytokines attract leucocytes to the damaged 
area and facilitate their degranulation, 
contributing to cell necrosis. These relatively 
small inflammatory substances (20-30 kDa) 
can easily penetrate to the circulation, either 
through a disrupted BBB (sharp and 
pronounced rise) or through the glymphatic 
system (delayed and prolonged expression) 
and activate other immuno-inflammatory 
mechanism, like CRP excretion (Muroi et al., 
2011). IL-6, among others has a negative 
feed-back role in the necrotic and apoptotic 
processes by down-regulating TGFβ, and 
metalloproteases, inhibiting neutrophil 
diapedesis and converting the innate 
immunological processes to adaptive, 
through T-cell recruitment  (Erta et al., 
2012). It even promotes astrogliosis via 
NGAL, which contributes to microglia 
proliferation and transforming the astrocytes’ 
GFAP structure towards tissue remodelling 
and endothelial cells to stimulate 
angiogenesis (Yang and Wang, 2015). 
D. FABP, DDMR 
Both FABP and DDMR had excellent 
correlation from the initial neurological 
condition through the CVS development and 
finally to all the outcome measurements.  It 
indicates that both of them are part of highly 
sensitive and fast-reacting mechanisms and 
are interesting candidates for further 
neuromarker investigations. This rapid 
response quality is supported by previous 
findings (Fassbender et al., 1997; Peltonen et 
al., 1997).  
Fatty-acid transporting protein (FABP) in our 
samples had high initial values, decreasing 
rapidly and reaching its nadir on day 2 post 
ictal. It is contradictory to findings of others, 
as it was described in 22 patients with stroke 
that values peak after 24-48 h (Zimmermann-
Ivol et al., 2004). It cannot be explained with 
a wash out effect during an operation, as only 
7% of the poor-grade SAH patients were 
operated in this cohort. The rest of the 
patients were treated by coil-embolisation. 
Thereafter the FABP serum levels increased 
to a second peak on day 8, nonetheless 
merely in the unfavourable group, leaving the 
patients with favourable properties with 
normal values. As CVS correlates, as 
mentioned earlier closely to all the outcome 
measures, FABP separates the poor and 
favourable patient groups distinctively. This 
assigns bordering excellent prognostic 
properties both for DCI development and 
14 
 
status. There is, however, a temporal shift in 
reaction among the markers and the 
association to different pathological events 
during the course of the disease may help to 
identify in what order in the inflammation 
cascade they are activated.  In other words 
they reveal how fast the different markers 
react to stimuli. 
While TNFR1 demonstrated a continuously 
rising pattern throughout the study period, 
doubling in concentration in the unfavourable 
patient-group, the other markers (IL-6, CRP, 
NGAL) showed a distinctive peak round day 
3. CRP and IL-6 followed a one-peak pattern, 
although IL-6 returned to base-line, even in 
the unfavourable group by day 6. CRP, 
despite its peak on day 3, decreased slowly 
and persisted on a level many times higher 
on day 11-14 compared to normal (day 0). 
NGAL showed however a double-peaked 
curve, especially in the unfavourable group, 
with a second top on day 8.  It appears that 
this second increase coincides with the time-
frame of CVS development. As it happens, 
CVS correlates very closely to poor outcome 
in this test-cohort.  
 
In many aspects the brain’s reaction to 
trauma, stroke or haemorrhage is similar. 
Either ischemia initiates injury (stroke, 
hypoxia) or injury causes ischemia 
(haemorrhage, trauma) which again 
aggravates the injury (Erta et al., 2012). 
Figure 28 Part of the neuroinflammatory process, with special reference on the neuropanel’s 
inflammatory biomarkers (CRP, IL-6, TNRF1, NGAL. Modified after Erta, 2012 
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outcome by all the scales (AUCROC 0.80 - 
0.85).  It is interesting to note the co-
variation of the nadir of this biomarker with 
that of DDMR, which I discuss below.  
DDMR, a coagulation remnant is the other 
biomarker with excellent correlation to 
admission neurological status, demonstrating 
that the coagulo-fibrinolytic system is, 
actually the most rapid responsive 
mechanism in the body (Gruen et al., 2012). 
It is particularly important as it was 
suggested that microthrombosis was 
responsible for DCI the most traitorous 
complication of aSAH (Vergouwen et al., 
2008). In a previous study, the elevated level 
of DDMR measured on the first day after 
aSAH, was found in good correlation to 6 
month outcome (Peltonen et al., 1997). In 
our study, the DDMR’s initial values were 
four times the normal values, corresponding 
to the previously mentioned study. It fell 
rapidly to normal level until day 2, when it 
reached its nadir. Thereafter the level 
increased again to a plateau circa six times 
higher in the unfavourable group and three 
times above normal level in the favourable 
group where it stayed during the rest of the 
observation period of 11-14 days. Because of 
the clear difference between the two groups, 
DDMR is proved capable of predicting 
outcome.  
The concavity in the course of DDMR may 
be explained by the local routine use of iv. 
fibrinolytic agent, tranexamic acid, which is 
administered from the time of establishing a 
diagnosis until the aneurysm is secured 
(often within 24 h from admission) (Hillman 
et al., 2002). After the drug effect diminishes 
the fibrinolytic activity returns. 
Unsurprisingly, the DDMR level reflects the 
amount of blood in the haemorrhage, thereby 
the assumed mass-effect, although as it is 
coagulation specific, it cannot differentiate 
between localisation and thence the 
neurological consequence. As there are both 
positive studies (Fujii et al., 1997; Juvela and 
Siironen, 2006) and negative findings (Tseng 
et al., 2007) in the literature, a recent review 
article considers the evidence for using 
DDMR as a biomarker after aSAH is weak 
and inconsistent (Boluijt et al., 2015).  
  
CONCLUSION 
 We have established a pattern of CRP development during the first week after an 
aSAH, which was independent from the patients’ infectious status. 
 
 We could demonstrate a difference in this pattern between the patients with favourable 
and unfavourable disease development (complication, outcome). 
 
 We could correlate this difference in CRP development to outcome measures and 
build a prognostic model to predict long-term outcome.  
 
 In search for an even earlier predictor, we could identify CRP values already on day 2 
with nearly the same predictive strength as the whole weeks CRP development and in 
parity with initial neurology and superior to initial radiological assessment in 
endovascularly treated patients.  
 
 We demonstrated that Apolipoprotein E’s genetical polymorphism had no influence 
either on the incidence of aSAH, the complication development or the outcome after 
the disease in West Sweden. 
 
 We identified however, a single nucleotide polymorphism (SNP) on the 9th 
chromosome, which does seem to influence the incidence of intracranial aneurysm 
rupture in the West-Swedish population. 
 
 Finally, we have tested a novel biochip array neuropanel in a selection of aSAH 
patients and found that six of the nine neuromarkers correlated to cerebral vasospasm 
and outcome. Four of them could be used for prediction purposes, thereby proving this 
methods usefulness in aSAH patient monitoring.  
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FUTURE PERSPECTIVES 
 
These studies were aimed to increase our knowledge on some biochemical markers and 
genetical predispositions during the course of subarachnoid haemorrhage and test their 
usefulness in clinical settings.  
We have demonstrated the applicability of inflammation markers in general and CRP in 
particular, not only as a marker of infection, but more as an assessment of disease severity. 
These markers, together with specialised tissue factors (here neuromarkers) may help guide 
clinicians in decision making on adjusting monitoring, choosing between therapy options or 
planning rehabilitation alternatives.  
We have found a need for sequential sample-taking to follow the course of the disease or 
detect secondary events. It increases the credibility of the marker and reduces the possibility 
for confounding errors. With some markers, continuous or near-continuous sample-taking and 
measurements are available (e.g. microdialysis), with others it is on its way. 
Multiple biochip-array technique is one of these techniques which can provide custom-made 
investigating tools to diagnose and to follow different kinds of pathological processes, 
including aSAH, using a drop of blood, liquor or any other body fluid.  
Finally, we have added a piece to the mounting evidence demonstrating the connections 
between genetic inheritance and risk for aSAH. Mapping our genetical risk background is in 
the near future and it may affect our life-style, diet and prevention efforts to overcome our 
genetical fate and to modify this predisposition. It is already a reality with some oncological 
therapy decisions. The genetical predisposition may determine our preference in future 
therapy-choices in many more diseases.  
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